var title_f12_28_12736="Transfollicular penetration in pseudofolliculitis barbae";
var content_f12_28_12736=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Transfollicular penetration in pseudofolliculitis barbae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Entry of the hair into the interfollicular skin occurs prior to exiting of the hair from the follicle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_28_12736=[""].join("\n");
var outline_f12_28_12736=null;
var title_f12_28_12737="Shared AAs in DR2 and DR4";
var content_f12_28_12737=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F72185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F72185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 491px\">",
"   <div class=\"ttl\">",
"    Common amino acids in two HLA-DR alleles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 471px; height: 404px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Alpha (green) and beta (blue) chains of the HLA class II molecule join to form an antigen binding pocket or domain. DNA sequencing of the two DR antigens, HLA-DR4 and -DR2, associated with the development of anti-U1 RNP antibodies has revealed that they share a common set of amino acids in the beta chain at positions 26, 28, 30, 31, 32, 70 and 73. As shown, amino acids at these positions form a portion of the antigen binding pocket.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_28_12737=[""].join("\n");
var outline_f12_28_12737=null;
var title_f12_28_12738="Patient information: Emergency contraception (The Basics)";
var content_f12_28_12738=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15350\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?9/54/10093\">",
"         How to use birth control pills for emergency contraception",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?13/56/14211\">",
"         Patient information: Choosing birth control (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?23/32/24068\">",
"         Patient information: Emergency contraception (morning after pill) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Emergency contraception (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/emergency-contraception-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H47665825\">",
"      <span class=\"h1\">",
"       What is emergency contraception?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Emergency contraception is also called &ldquo;the morning after pill,&rdquo; or &ldquo;plan B.&rdquo; It is a way you can keep from getting pregnant if you recently had sex. A woman might use emergency contraception if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        She forgot to take her birth control pills",
"       </li>",
"       <li>",
"        A condom broke or slipped off during sex",
"       </li>",
"       <li>",
"        She had sex without using birth control",
"       </li>",
"       <li>",
"        She was raped",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H47665832\">",
"      <span class=\"h1\">",
"       Are there different types of emergency contraception?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. There are 2 types of emergency contraception. One type is pills. The other is a device that goes inside your body. It is called a copper intrauterine device. You may have heard it called an &ldquo;IUD.&rdquo; If you want an IUD, a nurse or doctor needs to put it in within 5 days of when you had sex. An IUD prevents pregnancy as long as it is in place. If you decide you want one, your doctor or nurse can tell you more about it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H47665839\">",
"      <span class=\"h1\">",
"       Do I need to see a doctor or nurse to get emergency contraception pills?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on the kind of pill you would like.",
"     </p>",
"     <p>",
"      There are 2 types of emergency contraception pills that are hormones:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        One type is called &ldquo;Plan B&reg; One-Step,&rdquo; or &ldquo;Next Choice&reg;.&rdquo; Anyone who is at least 17 years old can buy it without a prescription at many drug stores or at Planned Parenthood. (If you want to buy it, call ahead to the drug store to make sure they have it.) Women 16 years old and younger must have a prescription.",
"       </li>",
"       <li>",
"        The other pills that work for emergency contraception are really birth control pills, but you have to take more than 1 at a time to keep from getting pregnant. This approach works,",
"        <strong>",
"         but it is less effective than Plan B",
"        </strong>",
"        &reg;",
"        <strong>",
"         One-Step, or Next Choice",
"        </strong>",
"        &reg;",
"        <strong>",
"         , and it is more likely to cause nausea.",
"        </strong>",
"        This table tells you which birth control pills you can use for emergency contraception, which color pills to take, and how many (",
"        <a class=\"graphic graphic_table graphicRef74604 \" href=\"UTD.htm?9/54/10093\">",
"         table 1",
"        </a>",
"        ). Birth control pills require a prescription.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      A third kind of emergency contraception pill is called &ldquo;ella&reg;.&rdquo; It is not a hormone and is available only by prescription.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H47665846\">",
"      <span class=\"h1\">",
"       When do I take emergency contraception?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Take the pills as soon as possible after you have sex. The pills can work up to 5 days after you have sex.",
"     </p>",
"     <p>",
"      Hormonal emergency contraception works best if you take it within 3 days of having unprotected sex. It is less effective if you take it 3 to 5 days after unprotected sex. If it has been 3 or more days since you had unprotected sex, ella&reg; might be a better option for you. It is more effective than hormonal emergency contraception from 3 to 5 days after unprotected sex.",
"     </p>",
"     <p>",
"      If you have sex again after you take the pills, you can still get pregnant. Make sure you use a condom or another type of birth control if you have sex again after you took emergency contraception.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H47665853\">",
"      <span class=\"h1\">",
"       What if I throw up?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Emergency contraception pills make some women throw up. If you throw up less than an hour after you take the pills, you have to take them again. Before you take them again, take a medicine that helps keep you from throwing up called",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?13/33/13844?source=see_link\">",
"       meclizine",
"      </a>",
"      . You can get meclizine without a prescription. It is sold in drug stores under the brand names Antivert&reg;, Bonine&reg;, Dramamine&reg;, and Medi-Meclizine. If you find you throw up with birth control pills, try Plan B&reg; One Step or Next Choice&reg; instead. These medicines are less likely to make you throw up.",
"     </p>",
"     <p>",
"      If you throw up within 3 hours of taking ella&reg;, call your doctor or nurse. He or she can tell you if you should take another pill.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H47665860\">",
"      <span class=\"h1\">",
"       Get it before you need it",
"      </span>",
"      &nbsp;&mdash;&nbsp;Even though hormonal emergency contraception is sold without a prescription, it is not always easy to find. Buy some today&mdash;even if you don&rsquo;t need it. That way you will have it at home, just in case.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H47665867\">",
"      <span class=\"h1\">",
"       What happens after I take emergency contraception?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should get your period within a week of when you expect it. If you took ella&reg;, don&rsquo;t be surprised if your period is a few days late. That&rsquo;s normal. But if you do",
"      <strong>",
"       not",
"      </strong>",
"      get your period within 3 or 4 weeks, no matter which form of emergency contraception you took, get a pregnancy test. The pills may not have worked. If you keep bleeding or have pain in your belly, see your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H47665874\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/56/14211?source=see_link\">",
"       Patient information: Choosing birth control (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/32/24068?source=see_link\">",
"       Patient information: Emergency contraception (morning after pill) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?12/28/12738?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15350 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-543E46505B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_28_12738=[""].join("\n");
var outline_f12_28_12738=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H47665825\">",
"      What is emergency contraception?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H47665832\">",
"      Are there different types of emergency contraception?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H47665839\">",
"      Do I need to see a doctor or nurse to get emergency contraception pills?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H47665846\">",
"      When do I take emergency contraception?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H47665853\">",
"      What if I throw up?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H47665860\">",
"      Get it before you need it",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H47665867\">",
"      What happens after I take emergency contraception?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H47665874\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15350\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/54/10093\">",
"      How to use birth control pills for emergency contraception",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/56/14211?source=related_link\">",
"      Patient information: Choosing birth control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/32/24068?source=related_link\">",
"      Patient information: Emergency contraception (morning after pill) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_28_12739="Granulomatous cheilitis 2";
var content_f12_28_12739=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F78861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F78861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Granulomatous cheilitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Granulomatous cheilitis is a rare disorder in which recurrent swelling of the lips leads to permanent areas of enlargement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_28_12739=[""].join("\n");
var outline_f12_28_12739=null;
var title_f12_28_12740="Angiogram_Total anomalous pulmonary venous connection";
var content_f12_28_12740=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/65581/tapvrang_conv.mp4?title=Angiogram_Total+anomalous+pulmonary+venous+connection\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Angiogram showing mixed pulmonary venous return of the left lung in a patient with total anomalous pulmonary venous connection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 452px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The left upper pulmonary vein connects to the left innominate vein via a vertical vein. The left lower pulmonary vein, along with the right pulmonary veins (not shown), drain through a dilated coronary sinus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Brian Soriano.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_28_12740=[""].join("\n");
var outline_f12_28_12740=null;
var title_f12_28_12741="Pegfilgrastim: Drug information";
var content_f12_28_12741=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pegfilgrastim: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/44/32452?source=see_link\">",
"    see \"Pegfilgrastim: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/29/43476?source=see_link\">",
"    see \"Pegfilgrastim: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F206840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Neulasta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Neulasta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F206855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Colony Stimulating Factor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F206842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not administer in the period between 14 days before and 24 hours after administration of cytotoxic chemotherapy. According to the NCCN guidelines, efficacy has been demonstrated with every-2-week chemotherapy regimens, however, benefit has not been demonstrated with regimens under a two-week duration (NCCN Myeloid Growth Factor Guidelines, v.1.2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prevention of chemotherapy-induced neutropenia:",
"     </b>",
"     SubQ: 6 mg once per chemotherapy cycle, beginning 24-72 hours after completion of chemotherapy",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F206850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/29/43476?source=see_link\">",
"      see \"Pegfilgrastim: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Do not administer in the period between 14 days before and 24 hours after administration of cytotoxic chemotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prevention of chemotherapy-induced neutropenia:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children (unlabeled dose): SubQ: 100 mcg/kg (maximum dose: 6 mg) once per chemotherapy cycle, beginning 24-72 hours after completion of chemotherapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adolescents &gt;45 kg: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F206843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F1628163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F206826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neulasta&reg;: 6 mg/0.6 mL (0.6 mL) [contains natural rubber/natural latex in packaging]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F206813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F206829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer subcutaneously. Do not use 6 mg fixed dose in infants, children, or adolescents &lt;45 kg. Engage/activate needle guard following use to prevent accidental needlesticks.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F206828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To decrease the incidence of infection, by stimulation of granulocyte production, in patients with nonmyeloid malignancies receiving myelosuppressive therapy associated with a significant risk of febrile neutropenia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2839880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Neulasta&reg; may be confused with Neumega&reg;, Neupogen&reg;, Nuedexta&trade;, and Lunesta&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F206853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system:  Headache (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Bone pain (31% to 57%), myalgia (21%), arthralgia (16%), weakness (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Antibody formation (1% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute respiratory distress syndrome (ARDS), allergic reaction, anaphylaxis, cutaneous vasculitis, erythema, fever, flushing, hyperleukocytosis, hypoxia, injection site reactions (erythema, induration, pain), leukocytosis, rash, sickle cell crisis, splenic rupture, Sweet's syndrome (acute febrile dermatosis), urticaria. Cytopenias resulting from an antibody response to exogenous growth factors have been reported on rare occasions in patients treated with other recombinant growth factors.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F206832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pegfilgrastim, filgrastim, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F206816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergic reactions: Anaphylaxis, angioedema, skin rash, erythema, and urticaria have occurred primarily with the initial dose and may recur (possibly delayed) after discontinuation; close follow up for several days and permanent discontinuation are recommended for severe reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory distress syndrome: Acute respiratory distress syndrome (ARDS) has been reported with use; evaluate patients with pulmonary symptoms such as fever, lung infiltrates, or respiratory distress; withhold or discontinue pegfilgrastim if ARDS occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Splenic rupture: Rare cases of splenic rupture have been reported; patients must be instructed to report left upper quadrant pain or shoulder tip pain.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sickle cell disease: May precipitate sickle cell crises in patients with sickle cell disease; carefully evaluate potential risks and benefits.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cytotoxic chemotherapy: Do not use pegfilgrastim in the period 14 days before to 24 hours after administration of cytotoxic chemotherapy because of the potential sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy. Benefit has not been demonstrated with regimens under a two-week duration. Administration on the same day as chemotherapy is not recommended (NCCN Myeloid Growth Factor Guidelines, v.1.2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Delayed myelosuppression: Use has not been evaluated with patients receiving chemotherapy associated with delayed myelosuppression (eg, nitrosoureas, mitomycin).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: The 6 mg fixed dose should not be used in infants, children, and adolescents weighing &lt;45 kg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Radiation therapy recipients: Use has not been evaluated in patients receiving radiation therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Stem cell mobilization: Safety and efficacy have not been evaluated for peripheral blood progenitor cell (PBPC) mobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Latex: The packaging (needle cover) contains latex.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor growth factor: May potentially act as a growth factor for any tumor type, particularly myeloid malignancies; caution should be exercised when using in any malignancy with myeloid characteristics. Tumors of nonhematopoietic origin may have surface receptors for pegfilgrastim.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F206820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegloticase: May diminish the therapeutic effect of Pegfilgrastim.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F206822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F206834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated adverse effects and fetal loss. There are no adequate and well-controlled studies in pregnant women; use only if potential benefit to mother justifies the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F206845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F206833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Neulasta Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg/0.6 mL (0.6 mL): $4687.68",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F206824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Complete blood count (with differential) and platelet count should be obtained prior to chemotherapy. Leukocytosis (white blood cell counts 100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ) has been observed in &lt;1% of patients receiving pegfilgrastim. Monitor platelets and hematocrit regularly. Evaluate fever, pulmonary infiltrates, and respiratory distress; evaluate for left upper abdominal pain, shoulder tip pain, or splenomegaly. Monitor for sickle cell crisis (in patients with sickle cell anemia).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F206835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Neulasta (AT, AU, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Neulastim (AR, BR, CN, CO, EC, HK, ID, IL, IN, NZ, PE, SG, TH, UY);",
"     </li>",
"     <li>",
"      Neulastyl (PH);",
"     </li>",
"     <li>",
"      Neupopeg (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Peglasta (MY, PH, SG, TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F206815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates the production, maturation, and activation of neutrophils, pegfilgrastim activates neutrophils to increase both their migration and cytotoxicity. Pegfilgrastim has a prolonged duration of effect relative to filgrastim and a reduced renal clearance.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F206831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Half-life elimination: SubQ: Adults: 15-80 hours; Children (100 mcg/kg dose): ~20-30 hours (range: up to 68 hours)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Andre N, Kababri ME, Bertrand P, et al, &ldquo;Safety and Efficacy of Pegfilgrastim in Children With Cancer Receiving Myelosuppressive Chemotherapy,&rdquo;",
"      <i>",
"       Anticancer Drugs",
"      </i>",
"      , 2007, 18(3):277-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/28/12741/abstract-text/17264759/pubmed\" id=\"17264759\" target=\"_blank\">",
"        17264759",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Andre N, Milano E, Rome A, et al, &ldquo;Safety of Pegfilgrastim in Children&rdquo;,",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2008, 42(2):290.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/28/12741/abstract-text/18182474/pubmed\" id=\"18182474\" target=\"_blank\">",
"        18182474",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Becker PS, Wagle M, Matous S, et al, \"Spontaneous Splenic Rupture Following Administration of Granulocyte Colony-Stimulating Factor (G-CSF): Occurrence in an Allogeneic Donor of Peripheral Blood Stem Cells,\"",
"      <i>",
"       Biol Blood Marrow Transplant",
"      </i>",
"      , 1997, 3(1):45-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/28/12741/abstract-text/9209740/pubmed\" id=\"9209740\" target=\"_blank\">",
"        9209740",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donadieu J, Beaupain B, Rety-Jacob F, et al, \"Respiratory Distress and Sudden Death of a Patient With GSDIb Chronic Neutropenia: Possible Role of Pegfilgrastim,\"",
"      <i>",
"       Haematologica",
"      </i>",
"      , 2009, 94(8):1175-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/28/12741/abstract-text/19644144/pubmed\" id=\"19644144\" target=\"_blank\">",
"        19644144",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fox E, Jayaprakash N, Widemann BC, et al, &ldquo;Randomized Trial and Pharmacokinetic Study of Pegfilgrastim vs. Filgrastim in Children and Young Adults With Newly Diagnosed Sarcoma Treated With Dose Intensive Chemotherapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(18S):9020 [abstract 9020 from 2006 ASCO Annual Meeting Proceedings, Part I].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holmes FA, O&rsquo;Shaughnessy JA, Vukelja S, et al, &ldquo;Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once Per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(3): 727-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/28/12741/abstract-text/11821454/pubmed\" id=\"11821454\" target=\"_blank\">",
"        11821454",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaidar-Person O, Moskovitz M, Charas T, et al, \"Pegfilgrastim Overdose: Case Report and Review of the Literature,\"",
"      <i>",
"       Med Oncol",
"      </i>",
"      , 2011, 28(Suppl 1):S697-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/28/12741/abstract-text/21107754/pubmed\" id=\"21107754\" target=\"_blank\">",
"        21107754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kuendgen A, Fenk R, Bruns I, et al, &ldquo;Splenic Rupture Following Administration of Pegfilgrastim in a Patient With Multiple Myeloma Undergoing Autologous Peripheral Stem Cell Transplantation,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2006, 38(1):69-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/28/12741/abstract-text/16715114/pubmed\" id=\"16715114\" target=\"_blank\">",
"        16715114",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Myeloid Growth Factors,&rdquo; Version 1.2011. Available at  file://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riu G, Estefanell A, Nomdedeu M, et al, \"Overdose of Pegfilgrastim: Case Report,\"",
"      <i>",
"       Int J Clin Pharm",
"      </i>",
"      , 2012, 34(5):690-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/28/12741/abstract-text/22821554/pubmed\" id=\"22821554\" target=\"_blank\">",
"        22821554",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith TJ, Khatcheressian J, Lyman GH, et al, &ldquo;2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(19):3187-205.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/28/12741/abstract-text/16682719/pubmed\" id=\"16682719\" target=\"_blank\">",
"        16682719",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wolff AC, Jones RJ, Davidson NE, et al, &ldquo;Myeloid Toxicity in Breast Cancer in Patients Receiving Adjuvant Chemotherapy With Pegfilgrastim Support,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(15):2392-4.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10154 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-92069A6D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_28_12741=[""].join("\n");
var outline_f12_28_12741=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206840\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855049\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206855\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206842\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206850\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206843\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1628163\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206826\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206813\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206829\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206828\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2839880\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206853\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206832\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206816\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299830\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206820\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206822\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206834\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206845\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206833\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206824\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206835\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206815\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206831\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10154\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10154|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/44/32452?source=related_link\">",
"      Pegfilgrastim: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/29/43476?source=related_link\">",
"      Pegfilgrastim: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_28_12742="Photomicrograph of a BMU";
var content_f12_28_12742=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F75617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F75617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Photomicrograph of a basic multicellular unit (BMU)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 400px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A group of osteoclasts with tartrate-resistant acid phosphatase-positive red granules erodes through a trabecula in murine vertebral cancellous bone. Pale yellow erythrocytes are seen in the blood vessels that transported the osteoclast precursors to the erosion cavity. Trailing behind the osteoclasts, teams of teal-colored osteoblasts forming new bone are bringing up the rear. Teal-colored osteocytes buried individually in the mineralized matrix (beige) are seen above and below the BMU.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Weinstein RS, Jia D, Powers CC, et al. The skeletal effects of glucocorticoid excess override those of orchidectomy in mice. Endocrinology 2004; 145:1980. Copyright &copy; 2004 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_28_12742=[""].join("\n");
var outline_f12_28_12742=null;
var title_f12_28_12743="Intracytoplasmic mucin";
var content_f12_28_12743=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67385&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67385&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intracytoplasmic mucin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A mucicarmine stain illustrates intracytoplasmic mucin (arrow), which appears as a dark pink intracytoplasmic globule within the neoplastic cells of a solid lung adenocarcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_28_12743=[""].join("\n");
var outline_f12_28_12743=null;
var title_f12_28_12744="Internal concealment of drugs of abuse (body packing)";
var content_f12_28_12744=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Internal concealment of drugs of abuse (body packing)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/28/12744/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/28/12744/contributors\">",
"     Robert S Hoffman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/28/12744/contributors\">",
"     Lewis Nelson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/28/12744/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/28/12744/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/28/12744/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/28/12744/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/28/12744/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Body packers are persons who, voluntarily or through coercion, swallow, or insert drug-filled packets into a body cavity, generally in an attempt to smuggle them across secure borders. Body packing was first described in the medical literature in 1973 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]; however, anecdotal reports suggest the practice was utilized by drug traffickers at least a decade prior to recognition. Body stuffing, which involves acute ingestion of drugs to avoid imminent apprehension by authorities, is a separate but related practice that can lead to both mechanical obstruction and acute massive toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When body packers present to health care providers, it may be for one (or more) of the following reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The body packer is asymptomatic but in the custody of authorities and needs medical evaluation and monitoring.",
"     </li>",
"     <li>",
"      The body packer has signs of systemic drug toxicity from a ruptured packet.",
"     </li>",
"     <li>",
"      The body packer has developed symptoms of gastrointestinal obstruction or perforation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An overview of the internal concealment of drugs of abuse (ie, body packing) will be presented here; body stuffing is not discussed. General aspects of drug intoxication and the diagnosis and management of intoxication with drug frequently involved in internal concealment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=see_link\">",
"     \"Cocaine: Acute intoxication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=see_link\">",
"     \"Opioid intoxication in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Body packing is a worldwide phenomenon with case reports published in the United States, Europe, Asia, and Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. It is difficult to estimate the number of body packers who attempt to cross into the United States or other countries. However, this number may be increasing. As an example, between 1993 and 2005, 1250 confirmed body packers were apprehended at New York's John F Kennedy International Airport [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/13\">",
"     13",
"    </a>",
"    ]; however, in the months after the terrorist attacks of September 11, 2001, there was a 60 percent increase in the number of body packer arrests, although it is not clear if this is due to increased traffic, increased surveillance, or a combination of both factors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The internal concealment of drugs of abuse resulted in at least 50 deaths in the greater New York City area between 1990 and 2001, most of which were related to acute intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/14\">",
"     14",
"    </a>",
"    ]. Initially, body packers were predominantly young males, but subsequently there have been reports of pregnant women and children performing this role [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Cocaine and heroin are the drugs most often involved in body packing, but methamphetamine, hashish, ecstasy (methylenedioxymethamphetamine), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    have also been smuggled in this manner [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/3,8\">",
"     3,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83249577\">",
"    <span class=\"h1\">",
"     METHODS OF BODY PACKING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The internal concealment of drugs of abuse requires a packing method that allows ingestion or insertion and retrieval of intact packets at some remote time. Primitive wrapping methods, such as duct tape, condoms, or plastics bags tied at one end [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/2\">",
"     2",
"    </a>",
"    ], had a high rate of failure and have largely been replaced by a more sophisticated method involving several layers of latex and an outer wax coating (",
"    <a class=\"graphic graphic_picture graphicRef73477 \" href=\"UTD.htm?36/5/36945\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef51090 \" href=\"UTD.htm?15/60/16320\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/3,17\">",
"     3,17",
"    </a>",
"    ]. Each of these packets contains approximately 8 to 10 grams of drug. Body packers (or \"mules\") generally swallow between 50 to 100 drug containers prior to departure, but larger numbers may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/10\">",
"     10",
"    </a>",
"    ]. Occasionally, smaller numbers of packets may be inserted rectally or vaginally.",
"   </p>",
"   <p>",
"    After ingestion, antimotility drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    or",
"    <span class=\"nowrap\">",
"     diphenoxylate/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"      atropine",
"     </a>",
"     )",
"    </span>",
"    are used to slow intestinal motility. Once they arrive at their destination, body packers often use promotility drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/6/31847?source=see_link\">",
"     magnesium hydroxide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=see_link\">",
"     magnesium citrate",
"    </a>",
"    ) to promote packet expulsion and retrieval.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1688070\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many cases, body packers are identified by law enforcement officials and referred to clinicians for evaluation, management, and packet recovery. However, a substantial number of patients present to physicians with symptoms related to intestinal obstruction or drug toxicity. Either complication can be fatal if the underlying diagnosis is not recognized clinically.",
"   </p>",
"   <p>",
"    The diagnosis of body packing is made based upon a suggestive history, findings on the physical examination, and diagnostic imaging, usually a plain x-ray of the abdomen. An approach to diagnosis and further management of these patients is outlined in the attached table (",
"    <a class=\"graphic graphic_table graphicRef55939 \" href=\"UTD.htm?40/53/41820\">",
"     table 1",
"    </a>",
"    ). The clinical manifestations of opioid (eg, heroin) and cocaine toxicity are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=see_link&amp;anchor=H4#H4\">",
"     \"Opioid intoxication in adults\", section on 'Clinical features of overdose'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=see_link&amp;anchor=H6#H6\">",
"     \"Cocaine: Acute intoxication\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although body packers may provide unreliable information to avoid prosecution, every attempt should be made to elicit an accurate history that includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Drug being carried",
"     </li>",
"     <li>",
"      Type of packet wrapping (home-made or improvised wrapping is more likely to leak or rupture)",
"     </li>",
"     <li>",
"      Number of packets ingested",
"     </li>",
"     <li>",
"      Presence of gastrointestinal symptoms (eg, pain, distention, or obstipation) suggesting obstruction or perforation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is generally believed that most body packers know exactly the number and contents of their packages because they are required to deliver a given number upon arrival. Multiple motives could cause them to over-report the package number (to stay in the hospital) or under-report the number (to deliver a drug packet in the prison system).",
"   </p>",
"   <p>",
"    A thorough physical examination should be performed, with a focus on the following issues:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Physical evidence of body packing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Packets may be felt on abdominal, vaginal, or rectal examination, and provide clear evidence of body packing prior to diagnostic imaging. Such information is of particular importance when the patient is clinically unstable at presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Drug toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a &ldquo;toxic syndrome&rdquo; or &ldquo;toxidrome&rdquo; (a constellation of physical findings suggesting toxicity from a particular drug) suggests leakage of drug from a drug packet. The attached table summarizes the findings associated with common toxic syndromes (",
"    <a class=\"graphic graphic_table graphicRef71268 \" href=\"UTD.htm?43/6/44140\">",
"     table 2",
"    </a>",
"    ). The opioid toxic syndrome (seen with heroin) consists of a depressed mental status, decreased respirations, miotic pupils, and decreased bowel sounds. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Heroin toxicity'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=see_link\">",
"     \"Opioid intoxication in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cocaine toxic syndrome consists of agitation, hypertension, tachycardia, mydriatic pupils, and diaphoresis. Cocaine toxicity in a body packer can be life-threatening and requires immediate intervention. Patients with severe toxicity from a ruptured cocaine packet may present with seizures, myocardial ischemia, heart failure, ventricular arrhythmias, or coma. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Cocaine toxicity'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=see_link\">",
"     \"Cocaine: Acute intoxication\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Intestinal obstruction or perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bowel obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/2,18,19\">",
"     2,18,19",
"    </a>",
"    ] and perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/20,21\">",
"     20,21",
"    </a>",
"    ] occur more commonly than esophageal obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/22,23\">",
"     22,23",
"    </a>",
"    ] or perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/22\">",
"     22",
"    </a>",
"    ], but all have been reported. Abdominal distention, tenderness, and abnormal bowel sounds (which may be high-pitched, tinkling, or absent) all suggest bowel obstruction; peritoneal signs suggest bowel perforation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=see_link\">",
"     \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41770?source=see_link\">",
"     \"Evaluation of the adult with abdominal pain in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Radiographic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiography should be performed in patients suspected of body packing and begins with a screening examination, generally a plain abdominal radiograph or ultrasound. More advanced imaging studies (abdominal computed tomography (CT) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enhanced radiography) are indicated when a screening examination is negative in a patient in whom there is high suspicion of internal concealment. Abdominal CT or barium enhanced radiography are used more commonly following a known ingestion to guide surgical intervention and document clearance of all packets. CT, which is performed with water-soluble contrast, is preferable if perforation is suspected. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Plain abdominal radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic evaluation of the body packer generally begins with plain abdominal radiography. There are several signs on the plain abdominal radiograph that suggest body packing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repeating geometric patterns (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef59243 \" href=\"UTD.htm?38/15/39152\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef78845 \" href=\"UTD.htm?41/2/42030\">",
"       image 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef65449 \" href=\"UTD.htm?38/41/39568\">",
"       image 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A rim of air trapped between two condoms, making the drug packets stand out in relief (the \"double condom sign\") (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef59782 \" href=\"UTD.htm?18/33/18961\">",
"       image 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/24\">",
"       24",
"      </a>",
"      ]&nbsp;",
"     </li>",
"     <li>",
"      Air in the tied ends of condoms (the \"rosette sign\") [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/19,25\">",
"       19,25",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pooled data suggests that the sensitivity of a single abdominal film is 85 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/3\">",
"     3",
"    </a>",
"    ]. However, the true sensitivity is difficult to assess, and a substantial number of drug packets are not visualized on plain films [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/2,18,26\">",
"     2,18,26",
"    </a>",
"    ]. As an example, in a retrospective study radiologists provided with clinical information about each case could not reach agreement on the presence or absence of packets on a plain abdominal radiograph in 14 percent",
"    <span class=\"nowrap\">",
"     (41/279)",
"    </span>",
"    of studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/27\">",
"     27",
"    </a>",
"    ]. False positive studies can also occur in the setting of bladder stones, hardened stool (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78827 graphicRef57853 \" href=\"UTD.htm?36/28/37317\">",
"     image 5A-B",
"    </a>",
"    ), or intraabdominal calcifications (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57452 \" href=\"UTD.htm?35/38/36463\">",
"     image 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only a few studies describe the use of ultrasound to screen potential body packers, but these reports suggest that this technology has a diagnostic accuracy similar to plain radiography. In two small, blinded studies, ultrasound correctly identified the subjects with a positive abdominal radiograph [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/19,29\">",
"     19,29",
"    </a>",
"    ]. Another blinded study of 50 body packers compared ultrasound to traditional methods of screening (abdominal radiography or monitored stools) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/30\">",
"     30",
"    </a>",
"    ]. Ultrasound had a diagnostic accuracy of 94 percent and required only 5 to 10 minutes to perform. However, because of the high pretest probability among these subjects, all of whom had been retained by officials due to suspicion of body packing, the true accuracy of ultrasound remains undefined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Advanced abdominal imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced radiographic imaging (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    -enhanced abdominal radiography or contrast-enhanced abdominal computerized tomography (CT)) is indicated in one of two circumstances. Infrequently, it is used to diagnose body packers in whom the initial screening study (plain radiography) is negative, but in whom the index of suspicion is high. More often, these studies are used to confirm clearance of the gastrointestinal tract after treatment.",
"   </p>",
"   <p>",
"    Determining when to perform a study to confirm gastrointestinal clearance can be difficult. If the patient is reliable, packet count may be used. In most patients, a confirmatory study should be performed after the passage of three packet-free stools.",
"   </p>",
"   <p>",
"    CT and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    -enhanced radiography are both more sensitive than plain abdominal radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/26,31,32\">",
"     26,31,32",
"    </a>",
"    ]. Packets on CT may appear as foreign bodies surrounded by a rim of gas (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70495 \" href=\"UTD.htm?7/33/7701\">",
"     image 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50541 \" href=\"UTD.htm?1/7/1136\">",
"     image 8",
"    </a>",
"    ). Packets on barium radiography generally appear as filling defects. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Radiographic evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Urine drug testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of urinalysis in the detection of body packers is controversial. Sensitivities in larger studies have ranged from &gt;90 percent to &lt;40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/33\">",
"     33",
"    </a>",
"    ]. The disparate sensitivities of published trials lead us to believe that urinalysis should",
"    <strong>",
"     not",
"    </strong>",
"    be used as a screening test for potential body packers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Law enforcement field testing of the actual packet content, which provides an accurate drug profile in minutes, is the ideal test to determine packet content. In the event that such testing is unavailable, urinary toxicology testing may be an acceptable surrogate. In several reports, findings on urine toxicology tests have correlated well with the subsequently identified packet contents.",
"   </p>",
"   <p>",
"    However, negative urine toxicology tests in documented body packers are common. Furthermore, such testing may be misleading. As an example, in one case report the urine specimen from a cocaine body packer tested negative for cocaine but positive for opiates [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/34\">",
"     34",
"    </a>",
"    ]. However, once body packing has been confirmed, an initial negative urine screen that subsequently turns positive might diagnose or confirm packet leakage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a body packer has been identified, specific treatment depends upon the drug involved, as well as the presenting symptoms and signs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are asymptomatic can be managed expectantly, without surgery, with close monitoring in an intensive care setting until the passage of all packets is complete. This approach is supported by a number of large case series [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/10,35,36\">",
"     10,35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that treatment with whole bowel irrigation (WBI) be started with a",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/17/4374?source=see_link\">",
"      polyethylene glycol",
"     </a>",
"     /electrolyte",
"    </span>",
"    lavage solution (PEG-ELS) such as GoLytely&reg;, at a rate of 2 liters per hour. In practice, it is difficult for a patient to consume PEG-ELS voluntarily at a rate of 2 liters per hour, and a nasogastric tube is typically required to ensure an adequate rate of administration.",
"   </p>",
"   <p>",
"    WBI has been used safely in body packers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/37,38\">",
"     37,38",
"    </a>",
"    ], and probably helps speed passage of packets, although there are no controlled studies. We suggest that promotility drugs be given to patients being treated with PEG-ELS, as these drugs improve the tolerability of WBI and hasten drug removal [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/39\">",
"     39",
"    </a>",
"    ]. Either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    (500 mg IV)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    (10 mg IV) can be used to increase motility. There is no role for cathartics as they can lead to fluid and electrolyte abnormalities.",
"   </p>",
"   <p>",
"    There are no controlled studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC) in body packers and in general we do not suggest treatment with AC in this setting. AC may be more useful in body stuffers (those who ingest drugs to avoid imminent apprehension by authorities). In body packers, AC might improve outcomes in the event of a ruptured cocaine packet, but the large doses needed would be impractical and AC could be detrimental in the case of bowel perforation or if surgery or endoscopy were required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Heroin toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Body packers who present with heroin toxicity should be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    (Narcan). Naloxone is a competitive antagonist at the opioid receptor that reverses the depression in mental status, hypoventilation, pinpoint pupils, decreased bowel motility, and piloerection of opioid overdose. However, it does",
"    <strong>",
"     not",
"    </strong>",
"    reverse opioid-induced acute lung injury. Patients with opioid-induced acute lung injury are managed in accordance with current standards. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=see_link&amp;anchor=H4#H4\">",
"     \"Opioid intoxication in adults\", section on 'Clinical features of overdose'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=see_link&amp;anchor=H18#H18\">",
"     \"Opioid intoxication in adults\", section on 'Acute lung injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Enormous amounts of heroin are released when a single packet ruptures; consequently, very high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    may be required to reverse toxicity in body packers. In such patients, an appropriate initial dose is 2 to 5 mg IV, with repeat doses of 2 mg given every five minutes until the patient is responsive. The",
"    <strong>",
"     total",
"    </strong>",
"    amount given to achieve a response should then be given",
"    <strong>",
"     every",
"    </strong>",
"    hour as a continuous naloxone infusion until all packets have passed.",
"   </p>",
"   <p>",
"    Once the body packer with heroin toxicity has been stabilized with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    , he or she may be managed in a similar fashion to the asymptomatic body packer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cocaine toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Body packers who present with cocaine toxicity should receive immediate, emergent surgical evaluation and be taken to the operating room for surgical decontamination. There is no \"antidote\" for cocaine toxicity, and therefore no place for conservative management of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=see_link\">",
"     \"Cocaine: Acute intoxication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39545?source=see_link\">",
"     \"Evaluation and management of the cardiovascular complications of cocaine abuse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34649?source=see_link\">",
"     \"Pulmonary complications of cocaine abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pharmacologic stabilization of symptomatic cocaine toxicity is appropriate, but not definitive, and should not delay transfer to the operating room. Symptoms of profound cocaine toxicity and their treatment include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperthermia &ndash; Active external cooling (fan and mist, ice water immersion) and intravenous benzodiazepine therapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      1 to 2 mg IV, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      5 to 10 mg IV, repeated as necessary)",
"     </li>",
"     <li>",
"      Hypertension &ndash; Intravenous benzodiazepine therapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      1 to 2 mg IV, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      5 to 10 mg IV, repeated as necessary);",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34485?source=see_link\">",
"       phentolamine",
"      </a>",
"      , 1 to 5 mg IV;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      , 0.3 to 3",
"      <span class=\"nowrap\">",
"       mcg/kg/min;",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      , 0.25 to 0.5",
"      <span class=\"nowrap\">",
"       mcg/kg/min",
"      </span>",
"     </li>",
"     <li>",
"      Seizures &ndash; Intravenous benzodiazepine therapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      2 to 4 mg IV, repeat as necessary)",
"     </li>",
"     <li>",
"      Ventricular dysrhythmias &ndash; Intravenous benzodiazepine therapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      1 to 2 mg IV, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      5 to 10 mg IV, followed rapidly by hypertonic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      if the QRS complex is greater than 120 msec)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Obstruction or perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal obstruction or perforation occurs infrequently. Intestinal complications are more common than esophageal complications, but both are reported.",
"   </p>",
"   <p>",
"    The treatment of these patients is surgical. The patient with evidence of gastrointestinal perforation should undergo immediate exploratory laparotomy. One or more enterotomies can be made in the bowel; packets are then \"milked\" towards the enterotomy site or the anus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After surgical decontamination, the patient may require an advanced radiographic imaging study to document a clear GI tract, as packets may be missed during operative evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Advanced abdominal imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4448210\">",
"    <span class=\"h2\">",
"     Endoscopic removal of packets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although endoscopic removal is highly controversial, there are reports of successful endoscopic removal of drug packets [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12744/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. The risk associated with this approach is primarily packet perforation, which can release dangerous amounts of drug.",
"   </p>",
"   <p>",
"    With the sophisticated packaging now commonly used by body packers, we believe that endoscopy may be safe when performed in a highly controlled setting, especially when a packet is available to test its strength against the snare. Only asymptomatic patients are candidates for endoscopy and only when whole bowel irrigation has failed or is otherwise contraindicated. Since each packet requires repeated passage of the endoscope, endoscopy is generally only considered for removal of a remaining packet or a few packets that have failed to pass the pylorus. Surgical backup should be available in case packet rupture occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H291137\">",
"    <span class=\"h2\">",
"     Disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;All identified body packers should be admitted to an intensive care setting, regardless of symptoms. Patients may be discharged once all signs of toxicity have resolved, there is no radiologic evidence of internal packets, and they have passed three packet-free stools.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical toxicology consultation should be sought. Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    . The American College of Medical Toxicology (",
"    <a class=\"external\" href=\"file://www.acmt.net/\">",
"     www.acmt.net",
"    </a>",
"    ) maintains a list of medical toxicologists by state on its website.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Body packers are individuals who attempt to smuggle drugs, most frequently cocaine or heroin, by internal concealment. Most often, drug packets are swallowed, but they may be inserted into the rectum or vagina. Each packet contains approximately 8 to 10 grams of drug. Packers generally swallow between 50 to 100 drug containers, but larger numbers may be involved. (See",
"      <a class=\"local\" href=\"#H83249577\">",
"       'Methods of body packing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Body packers may present in custody and without symptoms, with signs of systemic drug toxicity if a packet ruptures, or with symptoms and signs from intestinal obstruction or perforation.",
"     </li>",
"     <li>",
"      Although body packers may be unreliable, every attempt should be made to elicit an accurate history that includes the following: drug being carried; type of packet wrapping; number of packets ingested; and, the presence of gastrointestinal symptoms (pain, distention, or obstipation) suggesting obstruction or perforation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'History and physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Packets may be felt on abdominal, vaginal, or rectal examination. The presence of a &ldquo;toxic syndrome&rdquo; or &ldquo;toxidrome&rdquo; (a constellation of physical findings suggesting toxicity from a particular drug) suggests leakage of drug from a drug packet. Of particular importance are symptoms and signs consistent with cocaine toxicity (agitation, hypertension, tachycardia, mydriatic pupils, and diaphoresis), which may be fatal given the large doses found in packets. The attached table summarizes the findings associated with common toxic syndromes (",
"      <a class=\"graphic graphic_table graphicRef71268 \" href=\"UTD.htm?43/6/44140\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Diagnosis of body packing is usually confirmed through radiographic imaging, usually a plain abdominal x-ray. Urinalysis is an unreliable method for screening potential body packers and should not be used for this purpose. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Radiographic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are asymptomatic can be managed expectantly, without surgery, with close monitoring in an intensive care setting until the passage of all packets is complete. We suggest that asymptomatic body packers be treated with whole bowel irrigation using a",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?4/17/4374?source=see_link\">",
"        polyethylene glycol",
"       </a>",
"       /electrolyte",
"      </span>",
"      lavage solution to promote clearance (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Asymptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Body packers who present with heroin toxicity should be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"       naloxone",
"      </a>",
"      . Enormous amounts of heroin are released when a single packet ruptures; consequently, very high doses of naloxone may be required to reverse toxicity. An appropriate initial dose is 2 to 5 mg IV, with repeat doses of 2 mg given every five minutes until the patient is responsive. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Heroin toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Body packers who present with cocaine toxicity should receive immediate, emergent surgical evaluation and be taken to the operating room for surgical decontamination. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Cocaine toxicity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/1\">",
"      Deitel M, Syed AK. Intestinal obstruction by an unusual foreign body. Can Med Assoc J 1973; 109:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/2\">",
"      McCarron MM, Wood JD. The cocaine 'body packer' syndrome. Diagnosis and treatment. JAMA 1983; 250:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/3\">",
"      Traub SJ, Hoffman RS, Nelson LS. Body packing--the internal concealment of illicit drugs. N Engl J Med 2003; 349:2519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/4\">",
"      Fineschi V, Centini F, Monciotti F, Turillazzi E. The cocaine \"body stuffer\" syndrome: a fatal case. Forensic Sci Int 2002; 126:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/5\">",
"      Cobaugh DJ, Schneider SM, Benitez JG, Donahoe MP. Cocaine balloon aspiration: successful removal with bronchoscopy. Am J Emerg Med 1997; 15:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/6\">",
"      Malbrain ML, Neels H, Vissers K, et al. A massive, near-fatal cocaine intoxication in a body-stuffer. Case report and review of the literature. Acta Clin Belg 1994; 49:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/7\">",
"      Bulstrode N, Banks F, Shrotria S. The outcome of drug smuggling by 'body packers'--the British experience. Ann R Coll Surg Engl 2002; 84:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/8\">",
"      Takekawa K, Ohmori T, Kido A, Oya M. Methamphetamine body packer: acute poisoning death due to massive leaking of methamphetamine. J Forensic Sci 2007; 52:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/9\">",
"      Rossi P, Manzelli A, Ricciardi E, et al. [Bodypackers syndrome. A case report and review of the literature]. Ann Ital Chir 2011; 82:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/10\">",
"      Booker RJ, Smith JE, Rodger MP. Packers, pushers and stuffers--managing patients with concealed drugs in UK emergency departments: a clinical and medicolegal review. Emerg Med J 2009; 26:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/11\">",
"      Sribanditmongkol P, Supasingsiripreecha W, Thampitak S, Junkuy A. Fatal heroin intoxication in body packers in northern Thailand during the last decade: two case reports. J Med Assoc Thai 2006; 89:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/12\">",
"      Olumbe AK, Kalebi AY. Death from body packer syndrome: case report. East Afr Med J 2004; 81:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/13\">",
"      Mandava N, Chang RS, Wang JH, et al. Establishment of a definitive protocol for the diagnosis and management of body packers (drug mules). Emerg Med J 2011; 28:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/14\">",
"      Gill JR, Graham SM. Ten years of \"body packers\" in New York City: 50 deaths. J Forensic Sci 2002; 47:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/15\">",
"      Cordero DR, Medina C, Helfgott A. Cocaine body packing in pregnancy. Ann Emerg Med 2006; 48:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/16\">",
"      Traub SJ, Kohn GL, Hoffman RS, Nelson LS. Pediatric \"body packing\". Arch Pediatr Adolesc Med 2003; 157:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/17\">",
"      Pidoto RR, Agliata AM, Bertolini R, et al. A new method of packaging cocaine for international traffic and implications for the management of cocaine body packers. J Emerg Med 2002; 23:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/18\">",
"      Caruana DS, Weinbach B, Goerg D, Gardner LB. Cocaine-packet ingestion. Diagnosis, management, and natural history. Ann Intern Med 1984; 100:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/19\">",
"      Hierholzer J, Cordes M, Tantow H, et al. Drug smuggling by ingested cocaine-filled packages: conventional x-ray and ultrasound. Abdom Imaging 1995; 20:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/20\">",
"      Hutchins KD, Pierre-Louis PJ, Zaretski L, et al. Heroin body packing: three fatal cases of intestinal perforation. J Forensic Sci 2000; 45:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/21\">",
"      Cawich SO, Downes R, Martin AC, et al. Colonic perforation: a lethal consequence of cannabis body packing. J Forensic Leg Med 2010; 17:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/22\">",
"      Johnson JA, Landreneau RJ. Esophageal obstruction and mediastinitis: a hard pill to swallow for drug smugglers. Am Surg 1991; 57:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/23\">",
"      Dunne JW. Drug smuggling by internal bodily concealment. Med J Aust 1983; 2:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/24\">",
"      Pinsky MF, Ducas J, Ruggere MD. Narcotic smuggling: the double condom sign. J Can Assoc Radiol 1978; 29:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/25\">",
"      Beerman R, Nunez D Jr, Wetli CV. Radiographic evaluation of the cocaine smuggler. Gastrointest Radiol 1986; 11:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/26\">",
"      Hartoko TJ, Demey HE, De Schepper AM, et al. The body packer syndrome--cocaine smuggling in the gastro-intestinal tract. Klin Wochenschr 1988; 66:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/27\">",
"      Sormaala MJ, Salonen HM, Mattila VM, et al. Feasibility of abdominal plain film images in evaluation suspected drug smuggler. Eur J Radiol 2012; 81:2118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/28\">",
"      Traub SJ, Hoffman RS, Nelson LS. False-positive abdominal radiography in a body packer resulting from intraabdominal calcifications. Am J Emerg Med 2003; 21:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/29\">",
"      Alzen G, Banning S, G&uuml;nther R. [Sonographic detectability of narcotic drug containers in the gastrointestinal tract. Experimental research in the dog]. Rofo 1987; 146:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/30\">",
"      Meijer R, Bots ML. Detection of intestinal drug containers by ultrasound scanning: an airport screening tool? Eur Radiol 2003; 13:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/31\">",
"      Marc B, Baud FJ, Aelion MJ, et al. The cocaine body-packer syndrome: evaluation of a method of contrast study of the bowel. J Forensic Sci 1990; 35:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/32\">",
"      Kersschot EA, Beaucourt LE, Degryse HR, De Schepper AM. Roentgenographical detection of cocaine smuggling in the alimentary tract. Rofo 1985; 142:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/33\">",
"      Bogusz MJ, Althoff H, Erkens M, et al. Internally concealed cocaine: analytical and diagnostic aspects. J Forensic Sci 1995; 40:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/34\">",
"      Nihira M, Hayashida M, Ohno Y, et al. Urinalysis of body packers in Japan. J Anal Toxicol 1998; 22:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/35\">",
"      de Prost N, Lefebvre A, Questel F, et al. Prognosis of cocaine body-packers. Intensive Care Med 2005; 31:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/36\">",
"      Schaper A, Hofmann R, Bargain P, et al. Surgical treatment in cocaine body packers and body pushers. Int J Colorectal Dis 2007; 22:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/37\">",
"      Farmer JW, Chan SB. Whole body irrigation for contraband bodypackers. J Clin Gastroenterol 2003; 37:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/38\">",
"      Hoffman RS, Smilkstein MJ, Goldfrank LR. Whole bowel irrigation and the cocaine body-packer: a new approach to a common problem. Am J Emerg Med 1990; 8:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/39\">",
"      Traub SJ, Su M, Hoffman RS, Nelson LS. Use of pharmaceutical promotility agents in the treatment of body packers. Am J Emerg Med 2003; 21:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/40\">",
"      Zimmerman JL. Poisonings and overdoses in the intensive care unit: general and specific management issues. Crit Care Med 2003; 31:2794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/41\">",
"      Robinson T, Birrer R, Mandava N, Pizzi WF. Body smuggling of illicit drugs: two cases requiring surgical intervention. Surgery 1993; 113:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/42\">",
"      de Beer SA, Spiessens G, Mol W, Fa-Si-Oen PR. Surgery for body packing in the Caribbean: a retrospective study of 70 patients. World J Surg 2008; 32:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/43\">",
"      Olmedo R, Nelson L, Chu J, Hoffman RS. Is surgical decontamination definitive treatment of \"body-packers\"? Am J Emerg Med 2001; 19:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/44\">",
"      Choudhary AM, Taubin H, Gupta T, Roberts I. Endoscopic removal of a cocaine packet from the stomach. J Clin Gastroenterol 1998; 27:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/45\">",
"      Sherman A, Zingler BM. Successful endoscopic retrieval of a cocaine packet from the stomach. Gastrointest Endosc 1990; 36:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12744/abstract/46\">",
"      Macedo G, Ribeiro T. Esophageal obstruction and endoscopic removal of a cocaine packet. Am J Gastroenterol 2001; 96:1656.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 327 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-42E0F5FCD1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_28_12744=[""].join("\n");
var outline_f12_28_12744=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83249577\">",
"      METHODS OF BODY PACKING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1688070\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Physical evidence of body packing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Drug toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Intestinal obstruction or perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Radiographic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Plain abdominal radiograph",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Advanced abdominal imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Urine drug testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Heroin toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cocaine toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Obstruction or perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4448210\">",
"      Endoscopic removal of packets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H291137\">",
"      Disposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/327\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/327|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/15/39152\" title=\"diagnostic image 1\">",
"      Drug packet radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/2/42030\" title=\"diagnostic image 2\">",
"      Drug packet ingestion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/41/39568\" title=\"diagnostic image 3\">",
"      Drug packets stomach plain XR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/33/18961\" title=\"diagnostic image 4\">",
"      Drug packets abdominal plain radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/15/24816\" title=\"diagnostic image 5A\">",
"      Inspissated stool",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/44/38592\" title=\"diagnostic image 5B\">",
"      Inspissated stool rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/38/36463\" title=\"diagnostic image 6\">",
"      False positive radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/33/7701\" title=\"diagnostic image 7\">",
"      Drug packets abdominal CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/7/1136\" title=\"diagnostic image 8\">",
"      Drug packet transverse CT image",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/327|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/5/36945\" title=\"picture 1\">",
"      Drug packet layers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/60/16320\" title=\"picture 2\">",
"      Drug packet exterior",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/327|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/53/41820\" title=\"table 1\">",
"      Body packing overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/6/44140\" title=\"table 2\">",
"      Poisoning syndromes - toxidromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=related_link\">",
"      Cocaine: Acute intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39545?source=related_link\">",
"      Evaluation and management of the cardiovascular complications of cocaine abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41770?source=related_link\">",
"      Evaluation of the adult with abdominal pain in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=related_link\">",
"      Opioid intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34649?source=related_link\">",
"      Pulmonary complications of cocaine abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=related_link\">",
"      Small bowel obstruction: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_28_12745="Clinical uses of dronedarone";
var content_f12_28_12745=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical uses of dronedarone",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/28/12745/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/28/12745/contributors\">",
"     Rod Passman, MD, MSCE",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/28/12745/contributors\">",
"     Elsa-Grace Giardina, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/28/12745/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/28/12745/contributors\">",
"     Mark S Link, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/28/12745/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/28/12745/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/28/12745/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H17494077\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     Dronedarone",
"    </a>",
"    , a noniodinated congener of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , was developed as an antiarrhythmic agent for the maintenance of sinus rhythm in patients with atrial fibrillation. Because of the molecular and structural differences between dronedarone and amiodarone, in particular the deletion of the iodine molecules which are present in amiodarone, researchers have hypothesized that dronedarone will have fewer thyroid and pulmonary effects than amiodarone. Clinical trials have shown the clinical use and short-term safety (up to 21 months) of dronedarone for the maintenance of sinus rhythm following cardioversion in patients with atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/1\">",
"     1",
"    </a>",
"    ]. The efficacy and tolerability of dronedarone in children and adolescents aged &lt;18 years have not been established.",
"   </p>",
"   <p>",
"    A review of the pharmacology of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    , its clinical uses, adverse effects, and drug interactions will be presented here. The clinical uses and toxicities of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    and the choice of antiarrhythmic agents in the management of atrial fibrillation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=see_link\">",
"     \"Clinical uses of amiodarone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"     \"Major side effects of amiodarone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17494085\">",
"    <span class=\"h1\">",
"     MECHANISMS OF ACTION AND PHARMOCOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     Dronedarone",
"    </a>",
"    is a class III antiarrhythmic agent and a potent blocker of multiple intracardiac ion channels with many electrophysiological properties in common with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/2\">",
"     2",
"    </a>",
"    ]. Like amiodarone, dronedarone has antiadrenergic (ie, beta blocking) properties and inhibits multiple transmembrane potassium currents, including the delayed rectifier current, the ultra rapid delayed rectifier current, the inward rectifier current, and the transient outward current. In addition, dronedarone blocks inward depolarizing sodium and L-type calcium currents.",
"   </p>",
"   <p>",
"    Limited pharmacokinetic data are available for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    and are derived primarily from data in the United States Food and Drug Administration (FDA) prescribing information and from data in the FDA briefing document [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/3\">",
"     3",
"    </a>",
"    ]. Dronedarone is approximately 70 to 94 percent absorbed after oral administration, but its absolute bioavailability is only approximately 15 percent due to significant first pass metabolism. Peak plasma concentrations are achieved within three to six hours. However, there is a significant food effect which increases plasma dronedarone concentrations between two- and three-fold when the drug is taken with",
"    <sup>",
"    </sup>",
"    food [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/3\">",
"     3",
"    </a>",
"    ]. Following the initiation of dronedarone 400 mg twice daily, steady-state plasma concentrations",
"    <sup>",
"    </sup>",
"    are reached within four to eight days [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/4\">",
"     4",
"    </a>",
"    ].",
"    <a class=\"external\" href=\"file://circ.ahajournals.org/cgi/content/full/120/7/636\">",
"    </a>",
"   </p>",
"   <p>",
"    The clearance of",
"    <sup>",
"    </sup>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    is principally nonrenal, with a terminal half-life",
"    <sup>",
"    </sup>",
"    of approximately 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/3\">",
"     3",
"    </a>",
"    ]. This is markedly shorter than the half life of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , which has an effective half-life of up to 50 days. Dronedarone is highly bound to plasma proteins and is not associated with significant tissue accumulation. Therefore, it has been postulated that systemic side effects secondary to long-term usage of the drug, such as liver toxicity, pulmonary fibrosis, or thyroid dysfunction will be minimized in comparison to amiodarone. However, long-term toxicity data are not yet available.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     Dronedarone",
"    </a>",
"    has been shown to increase serum creatinine by 10 to 15 percent, a change which appears to resolve once the drug is discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/5\">",
"     5",
"    </a>",
"    ]. A phase I trial of dronedarone (400 mg twice daily for seven days) in 12 healthy males reported a decrease in creatinine clearance of 18 percent (compared to placebo) without adverse effects on glomerular filtration rate or renal plasma flow [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/5\">",
"     5",
"    </a>",
"    ]. Partial inhibition of tubular organic cation transporters has been suggested as a mechanism to explain the decrease in creatinine clearance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17494101\">",
"    <span class=\"h1\">",
"     METABOLISM AND DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    400 mg twice daily (taken with morning and evening meals) is approved for the maintenance of normal sinus rhythm in patients with a history of atrial fibrillation or atrial flutter. Dronedarone is metabolized by the CYP3A4 system in the liver and has many potential drug interactions. As dronedarone primarily undergoes hepatic metabolism, its clearance may also be altered in patients with hepatic impairment. No dose adjustment is required in patients with renal insufficiency.",
"   </p>",
"   <p>",
"    The pharmacokinetics of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    in patients with severe hepatic impairment have not been assessed; however, administration of dronedarone to patients with severe hepatic impairment is contraindicated [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/3\">",
"     3",
"    </a>",
"    ]. Currently, there are no dosage adjustment recommendations for patients with moderate hepatic impairment; however, data provided from the manufacturer indicate that patients with moderate hepatic impairment achieve higher dronedarone values with the potential to rise to supra-therapeutic concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/3\">",
"     3",
"    </a>",
"    ]. Although no statistically significant between-group difference in dronedarone exposure was observed in patients with moderate hepatic impairment and healthy volunteers who both received dronedarone 400&thinsp;mg twice daily for seven days, patients with moderate hepatic impairment exhibited numerically higher dronedarone exposure values and a highly variable coefficient of variation (&gt;70 percent), indicating the potential for supra-therapeutic concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13754?source=see_link\">",
"     \"Drugs and the liver: Metabolism and mechanisms of injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     Dronedarone",
"    </a>",
"    is a moderate inhibitor of CYP3A4 in the liver. Co-administration with another potent CYP3A4 inhibitor may increase",
"    <sup>",
"    </sup>",
"    dronedarone exposure by as much as 25-fold. Consequently, dronedarone",
"    <sup>",
"    </sup>",
"    should",
"    <strong>",
"     not",
"    </strong>",
"    be coadministered with other potent CYP3A4 inhibitors including antifungal agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ), macrolide antibiotics (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ), or protease inhibitors.",
"    <sup>",
"    </sup>",
"    When coadministered with moderate CYP3A4 inhibitors such as",
"    <sup>",
"    </sup>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    , lower doses of the concomitant drugs should",
"    <sup>",
"    </sup>",
"    be used to avoid the possibility of severe bradycardia and atrioventricular conduction block.",
"    <sup>",
"    </sup>",
"    It is not recommended to drink grapefruit juice during treatment with dronedarone, as grapefruit juice also inhibits CYP3A4.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     Dronedarone",
"    </a>",
"    is also a CYP2D6 inhibitor and causes a modest increase",
"    <sup>",
"    </sup>",
"    in bioavailability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    in CYP2D6 extensive metabolizers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/6\">",
"     6",
"    </a>",
"    ].",
"    <a class=\"external\" href=\"file://circ.ahajournals.org/cgi/content/full/120/7/636\">",
"    </a>",
"    <sup>",
"    </sup>",
"    Dronedarone, like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , causes partial inhibition of tubular",
"    <sup>",
"    </sup>",
"    transport of creatinine, which leads to increases in serum creatinine",
"    <sup>",
"    </sup>",
"    concentration unrelated to a reduced glomerular filtration [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several drugs or classes of medications deserve special mention, as the risks associated with concomitant administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    are potentially significant [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://circ.ahajournals.org/cgi/content/full/120/7/636\">",
"    </a>",
"    <sup>",
"    </sup>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       Ketoconazole",
"      </a>",
"      and other potent CYP3A inhibitors &mdash; Repeated doses of ketoconazole, a strong CYP3A4 inhibitor, result in a 17-fold increase in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      exposure and a ninefold increase in the peak concentration (C",
"      <sub>",
"       max",
"      </sub>",
"      ). Concomitant use of ketoconazole as well as other potent CYP3A inhibitors such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"       nefazodone",
"      </a>",
"      is contraindicated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13754?source=see_link\">",
"       \"Drugs and the liver: Metabolism and mechanisms of injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      QT prolonging medications &mdash; Coadministration of drugs with the potential to prolong the QT interval (such as some phenothiazines, tricyclic antidepressants, some macrolide antibiotics, and Class I and III antiarrhythmics) is contraindicated due to the risk of inducing torsade de pointes-type ventricular tachycardia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=see_link&amp;anchor=H17#H17\">",
"       \"Overview of the acute management of tachyarrhythmias\", section on 'Torsades de pointes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       Digoxin",
"      </a>",
"      &mdash; Concomitant administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      and digoxin results",
"      <sup>",
"      </sup>",
"      in a 1.7- to 2.5-fold increase in digoxin exposure,",
"      <sup>",
"      </sup>",
"      likely due to a P-glycoprotein&ndash;mediated interaction in",
"      <sup>",
"      </sup>",
"      the kidney [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/4\">",
"       4",
"      </a>",
"      ]. As an example, one study noted that when compared with placebo, dronedarone administration was associated with an approximately 40 percent increase in digoxin levels [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/7\">",
"       7",
"      </a>",
"      ]. However, the number of patients with digoxin levels outside the normal range in the two groups did not differ. When dronedarone is used for the treatment of patients taking digoxin, digoxin levels should be monitored to allow for appropriate dose reductions, if necessary. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/13/25817?source=see_link\">",
"       \"Digitalis (cardiac glycoside) poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oral anticoagulants &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       Dronedarone",
"      </a>",
"      increases serum",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      exposure by 1.2-fold and does not cause clinically significant prolongation of INR values. Clinical trials have not identified a clinically significant interaction between dronedarone and warfarin [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. A small, single-center crossover trial evaluating the competitive thrombin inhibitor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      in 16 healthy volunteers demonstrated that dabigatran levels were increased when it was administered with dronedarone (1.7- to 2.0-fold greater than dabigatran alone) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/10\">",
"       10",
"      </a>",
"      ]. The increase was within the range seen with other dabigatran&ndash;drug combinations, and no dose adjustment has been recommended.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"       Rivaroxaban",
"      </a>",
"      levels can also increase when given concurrently with dronedarone, particularly in patients with decreased renal function [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/3\">",
"       3",
"      </a>",
"      ]. No large scale published studies regarding interactions of dronedarone with oral thrombin or factor Xa inhibitors are available.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       Metoprolol",
"      </a>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       Dronedarone",
"      </a>",
"      increases the bioavailability of metoprolol in CYP2D6 extensive metabolizers and induces an additive dronedarone dose-dependent negative inotropic effect [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/6\">",
"       6",
"      </a>",
"      ]. These effects are modest when taking dronedarone 400 mg twice daily, and no dose adjustment is necessary. Neither higher doses of dronedarone nor metoprolol combinations have been evaluated; however, the potential for more marked effects on left ventricular function could be expected with higher doses [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/6\">",
"       6",
"      </a>",
"      ]. In addition, while other beta blockers have not been reported, it is likely that a similar negative inotropic effect could result.",
"     </li>",
"     <li>",
"      Statins &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       Dronedarone",
"      </a>",
"      increases",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      exposure by 1.4- to 4-fold, which increases the potential for statin-induced myopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Grapefruit juice &mdash; Grapefruit juice is a moderate inhibitor of CYP3A and results in a three-fold increase in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      exposure and a 2.5 increase in Cmax. Therefore, patients should avoid beverages containing grapefruit juice when using dronedarone [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Calcium channel blockers &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       Verapamil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      are moderate CYP3A inhibitors and increase",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      exposure by approximately 1.4 to 1.7-fold [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17494705\">",
"    <span class=\"h1\">",
"     CLINICAL USES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety and efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    has been established in several randomized, placebo-controlled trials, mostly in patients in atrial fibrillation (AF) or atrial flutter, with a variety of primary endpoints including rates of successful maintenance of sinus rhythm following cardioversion, hospitalization for cardiac causes,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    death:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       Dronedarone",
"      </a>",
"      is primarily used for the maintenance of sinus rhythm in patients with paroxysmal or persistent AF or atrial flutter and no evidence of heart failure or left ventricular systolic function. (See",
"      <a class=\"local\" href=\"#H17494713\">",
"       'Maintenance of sinus rhythm'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H753328\">",
"       'Heart failure'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link\">",
"       \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although spontaneous cardioversion occasionally occurs following the initiation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      , its efficacy is low for chemical cardioversion, and other drugs should be used. (See",
"      <a class=\"local\" href=\"#H17494720\">",
"       'Chemical cardioversion of AF'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link\">",
"       \"Restoration of sinus rhythm in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      lowers the heart rate at rest and following exercise in patients with AF, it should",
"      <strong>",
"       NOT",
"      </strong>",
"      be used exclusively as a rate control medication given the greater likelihood of adverse cardiovascular events (based on the PALLAS trial preliminary results) and the availability of other agents for this purpose. (See",
"      <a class=\"local\" href=\"#H752786\">",
"       'Effect on cardiovascular mortality'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H17494777\">",
"       'Ventricular rate control in AF'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       Dronedarone",
"      </a>",
"      has been reported to significantly increase mortality in patients with recently decompensated NYHA class III and IV heart failure and, as such, is contraindicated in this population. Its effect on cardiovascular morbidity and mortality in patients with stable, less severe degrees of congestive heart failure due to left ventricular dysfunction remains undetermined. (See",
"      <a class=\"local\" href=\"#H752786\">",
"       'Effect on cardiovascular mortality'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H753328\">",
"       'Heart failure'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Little evidence has been published indicating that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      has any efficacy in the treatment of ventricular arrhythmias. Because of this, there is",
"      <strong>",
"       no role",
"      </strong>",
"      for dronedarone in the treatment of ventricular tachyarrhythmias. (See",
"      <a class=\"local\" href=\"#H154561\">",
"       'Ventricular arrhythmia/ICDs'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29193?source=see_link\">",
"       \"Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22952?source=see_link\">",
"       \"Management of nonsustained ventricular tachycardia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17494713\">",
"    <span class=\"h2\">",
"     Maintenance of sinus rhythm",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the maintenance of sinus rhythm in patients with AF,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    has been consistently shown to be more effective than placebo. In the ADONIS, EURIDIS, and DAFNE trials, patients treated with dronedarone compared with placebo had significantly longer times to first recurrence of AF and significantly greater chances of remaining in sinus rhythm at 6 and 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/1,11\">",
"     1,11",
"    </a>",
"    ]. As an example, the following significant benefits from dronedarone therapy were noted in the ADONIS and EURIDIS trials [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A longer time to first recurrence of AF compared to placebo (96 versus 41 days in EURIDIS, 158 versus 59 days in ADONIS, and 116 versus 53 days on pooled analysis)",
"     </li>",
"     <li>",
"      A significantly higher percentage of patients remaining in sinus rhythm at 12 months (36 versus 25 percent receiving placebo)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One trial directly compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , which has long been considered to be the most effective antiarrhythmic drug for the maintenance of sinus rhythm following cardioversion for atrial fibrillation (AF) or atrial flutter. The DIONYSOS trial was a double-blind trial of 504 patients with AF that randomly assigned patients to dronedarone or amiodarone [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients were followed for at least six months, with a primary composite endpoint of recurrence of AF (including unsuccessful electrical cardioversion, no spontaneous conversion, and no electrical cardioversion) or premature study drug discontinuation for intolerance or lack of efficacy. After 12 months of treatment, the primary composite endpoint was significantly more likely to have occurred in patients receiving dronedarone (75 versus and 59 percent in the amiodarone group, respectively; hazard ratio [HR] 1.59; 95% CI 1.28-1.98). This result was mainly driven by a more frequent recurrence of AF in the dronedarone group (64 versus 42 percent with amiodarone). However, there was a trend toward less frequent study drug discontinuation for intolerance in the dronedarone group (10 versus 12 percent in the amiodarone group). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=see_link&amp;anchor=H17#H17\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials\", section on 'Dronedarone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon the DIONYSOS study,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    is less effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    for the maintenance of sinus rhythm in patients with AF. While short-term toxicities appear to be less common among patients taking dronedarone, there are limited data regarding long-term toxicities. Our recommendations regarding the role of dronedarone in the maintenance of sinus rhythm are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link&amp;anchor=H5304343#H5304343\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H752767\">",
"    <span class=\"h3\">",
"     Recommendations of major societies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both American and European cardiology societies have issued guidelines which specify subsets of patients in whom",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    should be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both the 2011",
"      <span class=\"nowrap\">",
"       ACC/AHA/HRS",
"      </span>",
"      Focused Update on the Management of Patients with Atrial Fibrillation and the 2010 European Society of Cardiology (ESC) Guidelines for the Management of Atrial Fibrillation list",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      among the first line antiarrhythmic agents for maintaining sinus rhythm in the following subsets of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with recurrent paroxysmal or persistent AF who have no (or minimal) heart disease",
"     </li>",
"     <li>",
"      Patients with recurrent paroxysmal or persistent AF and hypertensive heart disease without substantial left ventricular hypertrophy (LVH)",
"     </li>",
"     <li>",
"      Patients with recurrent paroxysmal or persistent AF and coronary artery disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In contrast to the",
"      <span class=\"nowrap\">",
"       ACC/AHA/HRS",
"      </span>",
"      Guidelines, the ESC guidelines also recommend the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      both in those patients with hypertensive heart disease and LVH along with stable class I or II congestive heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/14\">",
"       14",
"      </a>",
"      ]. However, a more recent report from the European Medicines Agency recommends that dronedarone should",
"      <strong>",
"       NOT",
"      </strong>",
"      be used in patients with heart failure or left ventricular systolic dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       Dronedarone",
"      </a>",
"      is contraindicated in patients with class IV heart failure or in patients who have had decompensated heart failure in the last four weeks, especially if they have moderate to severely reduced left ventricular ejection fraction (&lt;35 percent).",
"     </li>",
"     <li>",
"      While cardioversion alone may be desirable in some patients with persistent atrial fibrillation, loading with an antiarrhythmic drug prior to cardioversion is frequently employed in those patients deemed to be at high risk for AF recurrence. For these patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      should be initiated four or more days prior to cardioversion to achieve steady state levels and continued as maintenance therapy following cardioversion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17494720\">",
"    <span class=\"h2\">",
"     Chemical cardioversion of AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     Dronedarone",
"    </a>",
"    is only rarely effective for the chemical cardioversion of AF or atrial flutter to sinus rhythm (less than 10 percent of patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/11\">",
"     11",
"    </a>",
"    ]. As such, dronedarone should",
"    <strong>",
"     NOT",
"    </strong>",
"    be used for this purpose. However, as there is a potential for cardioversion during drug initiation, standard precautions should be taken to minimize the risk of thromboembolic events (ie, therapeutic anticoagulation for at least three weeks or a transesophageal echocardiogram for assessment of left atrial thrombus). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17494777\">",
"    <span class=\"h2\">",
"     Ventricular rate control in AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     Dronedarone",
"    </a>",
"    slows the resting ventricular heart rate by approximately 10 to 15 beats per minute in patients who develop recurrent AF and has been shown to reduce the maximum heart rate with exercise by up to 25 beats per minute [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/1,7,16\">",
"     1,7,16",
"    </a>",
"    ]. However, dronedarone should",
"    <strong>",
"     NOT",
"    </strong>",
"    be prescribed exclusively as a rate control medication given the availability of other agents for this purpose and the results of the PALLAS trial, which demonstrated an increase in cardiovascular mortality when dronedarone was used solely as a rate controlling agent. (See",
"    <a class=\"local\" href=\"#H752786\">",
"     'Effect on cardiovascular mortality'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17494734\">",
"    <span class=\"h2\">",
"     Changing to another antiarrhythmic drug",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who have developed recurrent AF despite antiarrhythmic therapy, it may be necessary to switch antiarrhythmic drugs. Because of the potential for QT prolongation and torsades des pointes, concomitant use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    and class I or III antiarrhythmic drugs (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"     table 1",
"    </a>",
"    ) that prolong the QT interval is contraindicated, and at least five half-lives should be allowed between changes in antiarrhythmic agents with the exception of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    . While there are no specific recommendations concerning the transition from amiodarone to dronedarone, clinical trial data describe three approaches:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In the ADONIS and EURIDIS trials,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      was initiated immediately upon discontinuation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the ERATO trial, patients underwent a two-month washout from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      prior to initiation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the ATHENA trial, patients discontinued",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      one month prior to initiating",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    can be started promptly after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    discontinuation, except in cases of clinically significant bradycardia or QT prolongation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H752786\">",
"    <span class=\"h2\">",
"     Effect on cardiovascular mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has never been any clear evidence of an overall mortality benefit with class I or class III antiarrhythmic medications (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"     table 1",
"    </a>",
"    ), including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    , when used for the maintenance of sinus rhythm. Early post-hoc analyses of dronedarone trials suggested that patients receiving dronedarone may have reduced cardiovascular mortality and stroke risk. However, a preliminary analysis of the PALLAS trial showed increased mortality when dronedarone was used solely as a rate controlling agent in patients with chronic AF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A post-hoc analysis of the EURIDIS and ADONIS trials described above reported reduced rates of hospitalization or death in patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/1\">",
"     1",
"    </a>",
"    ]. In the ATHENA trial, the largest trial of dronedarone to evaluate cardiovascular hospitalization and mortality, 4628 patients with AF who were thought to be at high risk of cardiovascular events were randomly assigned to receive dronedarone or placebo; patients with NYHA class IV heart failure were excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/17\">",
"     17",
"    </a>",
"    ]. When compared with placebo, dronedarone was associated with a significant reduction in cardiovascular mortality (2.7 versus 3.9 percent, HR 0.71, 95% CI 0.51-0.98) that was mostly due to a reduction in arrhythmic mortality.",
"   </p>",
"   <p>",
"    Based upon the results of the ATHENA trial, the PALLAS trial was designed to test the hypothesis that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    would improve major cardiovascular outcomes in patients with permanent rather than paroxysmal AF. Patients in PALLAS were treated with standard therapies for AF and then randomly assigned to dronedarone or placebo. The study was stopped early (3236 patients enrolled) after a significantly increased risk (HR 2.29, 95% CI 1.34-3.94) of cardiovascular events (cardiovascular death, myocardial infarction, stroke and systemic embolism) was observed in the dronedarone arm [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/18\">",
"     18",
"    </a>",
"    ]. The individual secondary end points of stroke, death from cardiovascular causes, and hospitalization for heart failure were also significantly increased in the dronedarone group. While patients enrolled in the PALLAS trial were older, had a higher prevalence of baseline comorbidities including heart failure compared with those enrolled in ATHENA, and were in chronic atrial fibrillation with no plans for rhythm control, we are concerned about these findings which further underscore the potential toxicities of AADs.",
"   </p>",
"   <p>",
"    Our recommendations regarding the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    for the maintenance of the sinus rhythm have not changed pending full peer review and publication of the PALLAS trial data. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link&amp;anchor=H58992353#H58992353\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\", section on 'Concerns about dronedarone'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link&amp;anchor=H440860149#H440860149\">",
"     \"Overview of atrial fibrillation\", section on 'Paroxysmal, persistent, longstanding persistent, or permanent AF'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H753328\">",
"    <span class=\"h3\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the increase in mortality in patients with moderate to severe heart failure,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    should",
"    <strong>",
"     NOT",
"    </strong>",
"    be used for the treatment of AF in such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link&amp;anchor=H5304343#H5304343\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ANDROMEDA trial was a randomized, double-blind trial comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    with placebo in 627 patients with a history of AF or atrial flutter hospitalized with symptomatic heart failure (NYHA III and IV) and a left ventricular ejection fraction &le;35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/19\">",
"     19",
"    </a>",
"    ]. The primary endpoint was death from any cause or hospitalization for worsening heart failure. The trial was stopped prematurely because of significantly increased mortality in the dronedarone arm (8 versus 4 percent in the placebo arm, HR 2.13, 95% CI 1.07 to 4.25). The excess mortality in the dronedarone arm was primarily due to heart failure, with the risk being highest in those with the most severely reduced left ventricular systolic function. There were no significant differences with respect to arrhythmic or sudden death and other nonfatal adverse events (except for higher serum creatinine levels in the dronedarone arm).",
"   </p>",
"   <p>",
"    In a 2012 meta-analysis of seven randomized controlled trials (10,676 patients) involving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    (six trials used placebo, and one trial used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    as the comparator), dronedarone use was associated with a non-significant trend toward higher cardiovascular and all-cause mortality but with significant heterogeneity in the outcomes (I",
"    <sup>",
"     2",
"    </sup>",
"    of 75 and 53 percent respectively), with ATHENA identified as the source of the heterogeneity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/20\">",
"     20",
"    </a>",
"    ]. When the data were reanalyzed following exclusion of the ATHENA data, the outcomes were homogeneous (I",
"    <sup>",
"     2",
"    </sup>",
"    of 0), with the risk of both cardiovascular (relative risk [RR] 2.33, 95% CI 1.49-3.64) and all-cause (RR 1.75, 95% CI 1.15-2.66) mortality significantly increased in users of dronedarone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154561\">",
"    <span class=\"h2\">",
"     Ventricular arrhythmia/ICDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other than a case report describing complete suppression of ventricular tachycardia that was resistant to multiple antiarrhythmic drugs and endocardial ablation, there are no clinical data evaluating the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    for the treatment of ventricular tachyarrhythmias or for the prevention of appropriate ICD shocks for ventricular tachycardia or ventricular fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/21\">",
"     21",
"    </a>",
"    ]. Pending further evidence of benefit, dronedarone should not be prescribed for the treatment of ventricular arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=see_link&amp;anchor=H31#H31\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29193?source=see_link&amp;anchor=H13#H13\">",
"     \"Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis\", section on 'Antiarrhythmic drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H155067\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with any medication, there are potential side effects with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    . While the most commonly encountered side effects are relatively benign (crampy abdominal pain, diarrhea, nausea, rash), rare but potentially life-threatening side effects may also be encountered. Knowledge of pre-existing comorbidities such as left ventricular systolic dysfunction, heart failure, or liver disease is crucial prior to prescribing dronedarone. Dronedarone should",
"    <strong>",
"     NOT",
"    </strong>",
"    be prescribed in patients with previous lung or liver toxicity due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Given the relatively short follow-up of patients enrolled in the clinical trials that evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    (mean 21 months), there is a paucity of data regarding potential long-term side effects. In view of this, hepatic function testing should be performed at the time of dronedarone initiation and repeated at three and six months. An electrocardiogram should be performed annually and at the time of any clinical change (ie, recurrent arrhythmia).",
"   </p>",
"   <p>",
"    The PALLAS trial was terminated early due to concerns about an increase in cardiovascular events (death, myocardial infarction, stroke, and systemic embolism) in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition, a 2012 meta-analysis of seven trials reported higher cardiovascular and all-cause mortality in patients receiving dronedarone. As such, patients with severe heart failure (HF) (generally those with NYHA class III or IV HF, or those who have been hospitalized with HF in the past four weeks) or those with an ejection fraction of &lt;35 percent should not receive dronedarone. (See",
"    <a class=\"local\" href=\"#H752786\">",
"     'Effect on cardiovascular mortality'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link&amp;anchor=H58992353#H58992353\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\", section on 'Concerns about dronedarone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H155075\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     Dronedarone",
"    </a>",
"    has been shown to result in a two-fold increase in HF mortality when administered to patients with moderate-to-severe left ventricular systolic dysfunction (EF &lt;35 percent) and recently decompensated (ie, within 30 days) HF [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/19\">",
"     19",
"    </a>",
"    ]. Dronedarone is contraindicated in such patients, and the drug should be discontinued if HF becomes exacerbated after drug initiation. Dronedarone should be used with caution if administered to patients with more stable forms of HF. (See",
"    <a class=\"local\" href=\"#H753328\">",
"     'Heart failure'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H155082\">",
"    <span class=\"h2\">",
"     ECG effects and arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major electrocardiographic effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    are bradycardia and QT prolongation, neither of which usually requires discontinuation of the drug. Torsades de pointes, while rare, has been reported, and dronedarone should be discontinued in this instance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/17,22\">",
"     17,22",
"    </a>",
"    ]. Abnormalities in potassium and magnesium levels must be corrected prior to drug initiation, other drugs that may affect the QT interval should be avoided, and caution should be used in patients at risk for QT interval prolongation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of the acute management of tachyarrhythmias\", section on 'Torsades de pointes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H155089\">",
"    <span class=\"h2\">",
"     Liver toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatocellular injury, including acute liver failure requiring transplant, has been reported with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    . The reported cases have occurred within six months of drug initiation. Assessment of hepatic function at baseline and within the first six months of treatment is recommended; intermittent long-term surveillance testing may also be reasonable [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3040933617\">",
"    <span class=\"h2\">",
"     Lung toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary toxicity has been reported with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12745/abstract/15\">",
"     15",
"    </a>",
"    ]. The time course, severity, and degree of reversibility have not been published. Routine lung surveillance is recommended, though no formal recommendations have been made on this matter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H155096\">",
"    <span class=\"h2\">",
"     Systemic adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"     Dronedarone",
"    </a>",
"    may result in other side effects in up to 10 percent of patients, including crampy abdominal pain, diarrhea, generalized weakness, nausea, and vomiting. Less frequently, patients develop dermatologic manifestations such as eczema, pruritus, skin inflammation, rash, and skin photosensitivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H155115\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       Dronedarone",
"      </a>",
"      is a class III antiarrhythmic agent that may be considered for the maintenance of sinus rhythm in patients with atrial fibrillation (AF). Dronedarone has many electrophysiological properties in common with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , including its antiadrenergic (ie, beta blocking) properties and the ability to inhibit multiple transmembrane potassium, sodium, and calcium currents. (See",
"      <a class=\"local\" href=\"#H17494085\">",
"       'Mechanisms of action and pharmocokinetics'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=see_link\">",
"       \"Clinical uses of amiodarone\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In contrast to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , which has an effective half-life of up to 50 days,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      has a half-life",
"      <sup>",
"      </sup>",
"      of approximately 24 hours. In addition, dronedarone is highly bound to plasma proteins and is not associated with the significant tissue accumulation seen with amiodarone. Therefore, it has been postulated that systemic side effects secondary to long-term usage of the drug, such as liver toxicity, pulmonary fibrosis, or thyroid dysfunction will be minimized in comparison to amiodarone. However, long-term toxicity data is not yet available. (See",
"      <a class=\"local\" href=\"#H17494085\">",
"       'Mechanisms of action and pharmocokinetics'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"       \"Major side effects of amiodarone\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Because of its hepatic metabolism, there are numerous potential drug interactions with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      . Concomitant use of dronedarone with some medications (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      , class I antiarrhythmic drugs) is contraindicated, while its use with other medications (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , statins) may require dose adjustment. (See",
"      <a class=\"local\" href=\"#H17494101\">",
"       'Metabolism and drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Trials have shown that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      is more effective than placebo but less effective than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      for the maintenance of sinus rhythm in patients with AF. However, dronedarone may be preferred in certain patient populations. (See",
"      <a class=\"local\" href=\"#H17494713\">",
"       'Maintenance of sinus rhythm'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link&amp;anchor=H523850628#H523850628\">",
"       \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\", section on 'Selecting an antiarrhythmic drug'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       Dronedarone",
"      </a>",
"      (400 mg twice daily) is used for the maintenance of sinus rhythm in patients with paroxysmal or persistent AF or atrial flutter and no evidence of heart failure or left ventricular systolic function who have spontaneously reverted to sinus rhythm or in whom cardioversion is planned. Hepatic function testing should be performed at the time of dronedarone initiation and repeated once or twice within the first six months and yearly thereafter. An electrocardiogram should be performed annually and at the time of any clinical change (ie, recurrent arrhythmia). (See",
"      <a class=\"local\" href=\"#H17494713\">",
"       'Maintenance of sinus rhythm'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       Dronedarone",
"      </a>",
"      should",
"      <strong>",
"       NOT",
"      </strong>",
"      be prescribed exclusively as a rate control medication given the availability of other agents for this purpose and the results of the PALLAS trial, which demonstrated an increase in cardiovascular mortality when dronedarone was used solely as a rate controlling agent. (See",
"      <a class=\"local\" href=\"#H17494777\">",
"       'Ventricular rate control in AF'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H752786\">",
"       'Effect on cardiovascular mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       Dronedarone",
"      </a>",
"      is only rarely effective for the chemical cardioversion of AF or atrial flutter to sinus rhythm (less than 10 percent of patients). As such, dronedarone should",
"      <strong>",
"       NOT",
"      </strong>",
"      be used for this purpose. However, as there is a potential for cardioversion during drug initiation, standard precautions should be taken to minimize the risk of thromboembolic events (ie, therapeutic anticoagulation for at least three weeks or a transesophageal echocardiogram for assessment of left atrial thrombus). (See",
"      <a class=\"local\" href=\"#H17494720\">",
"       'Chemical cardioversion of AF'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       Dronedarone",
"      </a>",
"      is usually well tolerated. Common side effects include crampy abdominal pain, diarrhea, nausea, and rash. Rare but potentially life-threatening side effects include heart failure, QT prolongation, and liver toxicity. Preliminary unpublished data from the PALLAS trial show an increased risk of cardiovascular events including death, myocardial infarction, stroke, and systemic embolism when dronedarone was administered to patients with chronic AF. There is a paucity of data regarding potential long-term side effects. Liver and lung toxicity have been reported, and routine surveillance for these adverse events is recommended. (See",
"      <a class=\"local\" href=\"#H155067\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who have developed recurrent AF despite antiarrhythmic therapy, it may be necessary to switch antiarrhythmic drugs. Because of the potential for QT prolongation and torsades des pointes, concomitant use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      and class I or III antiarrhythmic drugs (",
"      <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"       table 1",
"      </a>",
"      ) that prolong the QT interval is contraindicated, and at least five half-lives should be allowed between changes in antiarrhythmic agents with the exception of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      . While there are no specific recommendations concerning the transition from amiodarone to dronedarone, dronedarone can usually be started immediately after amiodarone discontinuation unless there is clinically significant bradycardia or QT prolongation. (See",
"      <a class=\"local\" href=\"#H17494734\">",
"       'Changing to another antiarrhythmic drug'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12745/abstract/1\">",
"      Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007; 357:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12745/abstract/2\">",
"      Varr&oacute; A, Tak&aacute;cs J, N&eacute;meth M, et al. Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. Br J Pharmacol 2001; 133:625.",
"     </a>",
"    </li>",
"    <li>",
"     MULTAQ Dronedarone tablets prescribing information products.sanofi.us/Multaq/Multaq.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12745/abstract/4\">",
"      Hoy SM, Keam SJ. Dronedarone. Drugs 2009; 69:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12745/abstract/5\">",
"      Tschuppert Y, Buclin T, Rothuizen LE, et al. Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol 2007; 64:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12745/abstract/6\">",
"      Damy T, Pousset F, Caplain H, et al. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. Fundam Clin Pharmacol 2004; 18:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12745/abstract/7\">",
"      Davy JM, Herold M, Hoglund C, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J 2008; 156:527.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12745/abstract/8\">",
"      Shirolkar SC, Fiuzat M, Becker RC. Dronedarone and vitamin K antagonists: a review of drug-drug interactions. Am Heart J 2010; 160:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12745/abstract/9\">",
"      Patel C, Yan GX, Kowey PR. Dronedarone. Circulation 2009; 120:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12745/abstract/10\">",
"      Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12745/abstract/11\">",
"      Touboul P, Brugada J, Capucci A, et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J 2003; 24:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12745/abstract/12\">",
"      Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol 2010; 21:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12745/abstract/13\">",
"      Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm 2011; 8:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12745/abstract/14\">",
"      European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/09/news_detail_001344.jsp&amp;murl=menus/news_and_events/news_and_events.jsp&amp;mid=WC0b01ac058004d5c1. (Accessed on September 22, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12745/abstract/16\">",
"      Page RL, Connolly SJ, Crijns HJ, et al. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). Am J Cardiol 2011; 107:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12745/abstract/17\">",
"      Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12745/abstract/18\">",
"      Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011; 365:2268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12745/abstract/19\">",
"      K&oslash;ber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358:2678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12745/abstract/20\">",
"      Chatterjee S, Ghosh J, Lichstein E, et al. Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure. Am J Cardiol 2012; 110:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12745/abstract/21\">",
"      Shaaraoui M, Freudenberger R, Levin V, Marchlinski FE. Suppression of ventricular tachycardia with dronedarone: a case report. J Cardiovasc Electrophysiol 2011; 22:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12745/abstract/22\">",
"      Kao DP, Hiatt WR, Krantz MJ. Proarrhythmic potential of dronedarone: emerging evidence from spontaneous adverse event reporting. Pharmacotherapy 2012; 32:767.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16216 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-D9A34E86B4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_28_12745=[""].join("\n");
var outline_f12_28_12745=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H155115\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17494077\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17494085\">",
"      MECHANISMS OF ACTION AND PHARMOCOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17494101\">",
"      METABOLISM AND DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17494705\">",
"      CLINICAL USES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17494713\">",
"      Maintenance of sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H752767\">",
"      - Recommendations of major societies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17494720\">",
"      Chemical cardioversion of AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17494777\">",
"      Ventricular rate control in AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17494734\">",
"      Changing to another antiarrhythmic drug",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H752786\">",
"      Effect on cardiovascular mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H753328\">",
"      - Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154561\">",
"      Ventricular arrhythmia/ICDs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H155067\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H155075\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H155082\">",
"      ECG effects and arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H155089\">",
"      Liver toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3040933617\">",
"      Lung toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H155096\">",
"      Systemic adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H155115\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/16216\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/16216|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/52/2892\" title=\"table 1\">",
"      Vaughan Williams classification of antiarrhythmic drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=related_link\">",
"      Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=related_link\">",
"      Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=related_link\">",
"      Clinical uses of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/13/25817?source=related_link\">",
"      Digitalis (cardiac glycoside) poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13754?source=related_link\">",
"      Drugs and the liver: Metabolism and mechanisms of injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22952?source=related_link\">",
"      Management of nonsustained ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=related_link\">",
"      Overview of the acute management of tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29193?source=related_link\">",
"      Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_28_12746="The natural history of childhood food allergy";
var content_f12_28_12746=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The natural history of childhood food allergy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/28/12746/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/28/12746/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/28/12746/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/28/12746/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/28/12746/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/28/12746/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/28/12746/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Understanding the natural history of food allergy in childhood is essential in managing patients with these disorders. The natural history of a food allergy includes information on the acquisition of the allergy, the likelihood that it will be outgrown, and its usual duration.",
"   </p>",
"   <p>",
"    Food allergy most often begins in the first two years of life. Certain food allergies, such as those to cow's milk and hen's egg, are usually outgrown during childhood or adolescence, whereas peanut and tree nut allergies are more likely to persist into adulthood.",
"   </p>",
"   <p>",
"    This topic review provides an overview of the natural history of food allergy in children. The clinical manifestations and treatment of food allergy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=see_link\">",
"     \"Clinical manifestations of food allergy: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION OF FOOD ALLERGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this section, the terms \"allergy\" and \"hypersensitivity\" are used interchangeably to refer to an abnormal immunologic reaction to food. Such reactions can be mediated by IgE molecules directed against specific food proteins that activate mast cells and basophils, or can arise from other cellular processes involving eosinophils or T cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=see_link\">",
"     \"Clinical manifestations of food allergy: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREVALENCE OF CHILDHOOD FOOD ALLERGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most food allergy is acquired in the first or second year of life. The peak prevalence of food allergy is approximately 6 to 8 percent at one year of age, although rates as high as 10 percent have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. It then falls progressively until late childhood, after which the prevalence remains stable at about 3 to 4 percent.",
"   </p>",
"   <p>",
"    Parentally-perceived food allergy is common in early childhood, with up to one-third of parents reporting one or more adverse food reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/5-10\">",
"     5-10",
"    </a>",
"    ]. Parentally-reported adverse food reactions were assessed with a prospective study of 3623 children, followed from birth until the age of two [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/5,6,11\">",
"     5,6,11",
"    </a>",
"    ]. Parents completed questionnaires at six-month intervals. The cumulative incidence of adverse food reactions was 35 percent by age two. Cow's milk, fruits (especially citrus and strawberry), and vegetables (especially tomato), accounted for nearly two-thirds of all reported reactions. Cow's milk was the single food item most commonly incriminated, with a cumulative incidence of 12 percent. Other problematic foods reported by parents included egg (4.4 percent), fish (3 percent), nuts (2.1 percent), and cereals (1.4 percent). The overall duration of food reactivity was short, with approximately two-thirds of the reactions resolving within six months of their onset. The probable explanation for the brief duration of most of these reactions is the commonplace nature of irritant, non-immunologic food reactions in infants and young children. Mild perioral rashes after eating tomatoes or berries are examples, although IgE-mediated allergies to these foods are also possible.",
"   </p>",
"   <p>",
"    Variable criteria are used to measure food allergy. In studying IgE-mediated allergy, some researchers examine rates of \"sensitization,\" or the presence of IgE directed against a specific food, as detected by in vivo (skin testing) or in vitro testing for specific IgE (often called radioallergosorbent testing, or RAST, though nowadays the test uses fluorescence rather than radioactivity, and is termed FEIA for fluorescent-enzyme immunoassay). This is distinct from clinical reactivity, which is the development of symptoms on exposure to a food, as assessed by history or challenge. This distinction occurs because not all patients with detectable food-specific IgE antibodies will have a reaction when the food is ingested. Less commonly, patients may have clear histories of food allergic reactions with low or undetectable levels of food-specific IgE. Thus, studies measuring sensitization to food allergens may overestimate the prevalence of true food allergy.",
"   </p>",
"   <p>",
"    The German Multicenter Allergy Study followed the development of sensitization to common food allergens in a large cohort of children, without clinical confirmation of food reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. A total of 216 children from a birth cohort of 4082 children were assessed with serum food-specific IgE testing approximately yearly. The overall annual incidence rates for food sensitization decreased from a peak of 10 percent at age one, to 3 percent at age six. Sensitization to hen's egg and cow's milk were most common, with peak prevalence rates of about 6 percent at age one, followed by wheat and soy.",
"   </p>",
"   <p>",
"    In contrast, the rates of food allergy are significantly lower if allergy is defined by verified clinical reactivity upon ingestion. As an example, a cohort of 1749 children was followed from birth to determine the prevalence of cow's milk allergy during the first year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/15\">",
"     15",
"    </a>",
"    ]. The children were evaluated by history, milk elimination, oral challenge, and skin prick tests or serum food-specific IgE testing. A confirmed reactivity rate of 2.2 percent was reported.",
"   </p>",
"   <p>",
"    An association between early food allergy and later atopic respiratory conditions has been noted in multiple studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/12,15-17\">",
"     12,15-17",
"    </a>",
"    ]. A child with food allergy has between a 50 and 90 percent chance of subsequently developing asthma. Young children who are sensitized to food in infancy, particularly egg, often develop subsequent sensitization to aeroallergens. In one study, a serum RAST result for egg &gt;2",
"    <span class=\"nowrap\">",
"     kUA/L",
"    </span>",
"    at age 12 months was 99 percent specific and had a 77 percent positive predictive value for sensitization to respiratory allergens by three years, even in the absence of other risk factors, such as family history of atopy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, more than one-third of parents will report adverse food reactions in their young children, although the rates of verifiable food allergy are much lower. Food sensitization",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    allergy are present in 5 to 10 percent of young children with peak prevalence at about one year of age. Studies that measure sensitization to food allergens can overestimate the prevalence of true allergic reactions to foods, because not all sensitized children will develop symptoms upon ingestion. Young children who are sensitized to foods or have confirmed IgE-mediated food allergy are more likely than their non-allergic peers to develop allergic rhinitis and asthma later on.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OVERVIEW OF RESOLUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of childhood food allergies are lost over time, although the process of resolution varies a great deal among different foods and individual patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Food allergies to most foods, other than",
"    <span class=\"nowrap\">",
"     fish/shellfish",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     peanut/tree",
"    </span>",
"    nuts, are usually outgrown:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 82 children aged 6 months to 14 years with a variety of food allergies were followed for a period of two to five years [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/18\">",
"       18",
"      </a>",
"      ]. Of the 12 children who were allergic to cow's milk, four developed complete tolerance, seven had reduced sensitivity, and only one remained unchanged by the completion of the study. Of 55 children with egg allergy, 20 developed complete tolerance, 24 had reduced sensitivity, and 11 remained unchanged. These results are very different from those for fish and",
"      <span class=\"nowrap\">",
"       peanut/tree",
"      </span>",
"      nut allergy. Of 32 patients with fish allergy, only five developed tolerance and none of the 35 children with",
"      <span class=\"nowrap\">",
"       peanut/tree",
"      </span>",
"      nut allergy developed tolerance.",
"     </li>",
"     <li>",
"      In a similar study of 75 patients (between the ages of 3 and 18 years) with atopic dermatitis and food allergy, patients underwent yearly rechallenge with each of the foods that had previously elicited a positive reaction [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/19\">",
"       19",
"      </a>",
"      ]. Diagnoses of food allergy were made by skin testing, RASTs,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      double-blind, placebo-controlled food challenges (DBPCFC). After one to two years of follow-up, soy, wheat, egg, peanut, and cow's milk allergy had been lost in 50, 33, 24, 20, and 19 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies were not large enough to discern whether there were differences in the natural histories of children diagnosed in very early life compared to those diagnosed in later childhood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms by which food allergy resolves are not fully understood, and it is likely that multiple mechanisms are involved. Food-specific IgE levels tend to fall over time in most patients with food allergy, and this loss of IgE is the best known predictor of the development of clinical tolerance. However, it is also clear that some patients become tolerant even with persistently elevated food-specific IgE levels, and thus, loss of IgE is not a requirement for, or even the primary mechanism of the resolution of food allergy in these patients. Other humoral changes, including increased levels of allergen-specific IgG4",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mucosal IgA, may also play a role. Alternately, cellular changes, such as the induction of T regulatory cells, may be important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Role of avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strict dietary avoidance of the foods to which a child is allergic has been a mainstay of food allergy management, based upon the clinical impression that avoidance increases the chance of outgrowing an allergy and may hasten resolution. However, few studies address this issue [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In one study of children with egg allergy, neither strict avoidance nor accidental exposure, assessed by recall questionnaire, impacted the development of tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinician-supervised oral food challenges are often required to determine if an allergy has resolved. Clinical experience suggests that food challenges that result in an allergic reaction do not alter the natural course of resolution of food allergy, although studies have not specifically addressed this issue.",
"   </p>",
"   <p>",
"    Studies of oral food challenges reveal that individuals vary with regard to the threshold amount of food that triggers a reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/23\">",
"     23",
"    </a>",
"    ]. However, strict avoidance is generally advised, rather than having patients ingest an allergen in subthreshold amounts, because patients may accidentally consume a larger amount than intended and elicit an allergic reaction.",
"   </p>",
"   <p>",
"    Some children who react to whole egg (eg, scrambled) or dairy (eg, liquid milk, yogurt) can tolerate extensively heated forms of these allergens in smaller quantities in foods, such as baked muffins [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Data suggest that allowing this \"less strict\" avoidance hastens the development of tolerance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of food allergy: Avoidance\", section on 'How strict must avoidance be?'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13223?source=see_link&amp;anchor=H6#H6\">",
"     \"Egg allergy: Management\", section on 'Avoidance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40087?source=see_link&amp;anchor=H7#H7\">",
"     \"Milk allergy: Management\", section on 'Avoidance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients demonstrate sensitization to a food that they consume (eg, a positive allergen prick skin test or elevated specific serum IgE), but they do not have a clear history of reactions to that food. Several small case series have reported that invoking strict avoidance of the food occasionally results in acute and severe reactions to the self-same food upon reintroduction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. This phenomenon may represent a loss of a desensitized state to a food that was maintained while it was being regularly ingested. However, there are no formal studies assessing the risk of occurrence of this uncommon outcome, and removal of foods from the diet is often required to diagnose and treat chronic allergic conditions.",
"   </p>",
"   <p>",
"    In practice, some children rapidly outgrow their food allergies without strict avoidance and others, despite the most stringent diet, do not. Because strict avoidance is so difficult, it would be helpful to understand the impact of continued exposure on the natural history of food allergy. Until we do, however, it is still likely that the majority of children with food allergy will benefit from strict avoidance, at least to avoid provoking symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MONITORING THE FOOD-ALLERGIC CHILD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The food allergic child must be followed regularly by both the pediatrician and allergist to assure that growth and development are normal. The allergist should review all accidental exposures and food reactions in order to assure that avoidance measures are adequate, reactions are recognized promptly and treated appropriately, epinephrine autoinjectors are current and available to the child in all settings (if appropriate), and that the patient and caregivers understand the management plan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Serial testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The allergist should evaluate the child at regular intervals to determine if the allergy has been outgrown. This is usually done yearly; however, longer or shorter intervals may be more appropriate in some situations. As examples, a child with a reaction to fruit might be evaluated every six months, and an older child with persistent peanut allergy may not need annual testing after the first few years if there is no indication of improvement.",
"   </p>",
"   <p>",
"    Reevaluation can be accomplished with in vitro testing, skin prick testing, and information on accidental exposures. The optimal method of monitoring specific food allergies has not yet been determined, and various approaches can be used. We use the clinical history and in vitro testing (CAP-FEIA) to follow patients in our clinic. We generally do not perform repeat skin testing, as we feel it does not change our management in the majority of cases. However, other centers do use skin testing, especially in making decisions about whether or not to proceed to an oral challenge.",
"   </p>",
"   <p>",
"    In vitro testing for allergic disease is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=see_link\">",
"     \"Overview of in vitro allergy tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Determining if an allergy has resolved",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supervised food challenge is recommended to prove the condition has been outgrown, because negative tests do not guarantee loss of allergy with absolute certainty, and positive tests can persist even after an allergy has resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. These must be performed with caution and with full emergency equipment and medications on hand to treat possible reactions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=see_link\">",
"     \"Oral food challenges for diagnosis and management of food allergies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If there is no interim history to suggest a recent reaction, then we recommend the following reevaluation for children with specific childhood food allergies:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Cow's milk and egg",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgE-mediated allergies to milk and egg are usually lost gradually throughout childhood and adolescence. We retest yearly with CAP-FEIA testing. The rate of decline can predict the likelihood that a challenge will be negative. We usually offer challenge to milk and egg when the specific IgE level is &le;2",
"    <span class=\"nowrap\">",
"     kUA/L,",
"    </span>",
"    which gives the patient an approximately 50 percent chance of passing the challenge in our patient population. However, positive predictive values for both specific IgE and skin prick testing may vary depending on the population studied [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/32\">",
"     32",
"    </a>",
"    ]. Lower cutoffs may be used for children under two years of age. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Cow's milk'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H22\">",
"     'Hen's egg'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Non-IgE-mediated CMA tends to be outgrown more quickly and a careful challenge is warranted by the age of two to three years if there have been no recent reactions from accidental exposures. Reintroduction of food in dietary or food-protein induced enterocolitis syndrome (FPIES), in particular, is associated with significant risk. Challenges in patients with FPIES who were very ill upon presentation should be performed under close supervision in a hospital setting. This is reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Peanut or tree nut",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend repeat testing yearly with CAP-FEIA testing. Patients with TN- or PN-IgE level &le;2",
"    <span class=\"nowrap\">",
"     kUA/L",
"    </span>",
"    should be offered a supervised challenge. If negative, the patient should be advised to ingest nut at least once a week. The optimal amount of nut that patients should eat monthly is unknown. We therefore suggest that they ingest a serving (eg, the amount in a peanut butter sandwich or nut-containing candy bar). Patients should be followed for at least another year to assure that there are no recurrent symptoms.",
"   </p>",
"   <p>",
"    In patients with persistent allergy, or if the CAP-FEIA remains unchanged for several years, testing can be performed less frequently over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Wheat",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wheat-specific IgE level predictive of clinical reactivity has not been determined, due to poor performance characteristics of the IgE assay for this allergen [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/33\">",
"     33",
"    </a>",
"    ]. Proposed challenge decision points range from 20 to 100",
"    <span class=\"nowrap\">",
"     kU/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/31,34\">",
"     31,34",
"    </a>",
"    ]. In one survey, 60 percent of patients with a wheat IgE level &lt;20",
"    <span class=\"nowrap\">",
"     kU/L",
"    </span>",
"    passed their challenges and 50 percent of those with a wheat IgE level of &lt;50",
"    <span class=\"nowrap\">",
"     kU/L",
"    </span>",
"    passed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/35\">",
"     35",
"    </a>",
"    ]. Peak wheat-specific IgE has some predictive value in determining the age at which tolerance develops and higher levels may indicate risk of persistent allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Wheat allergy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We suggest that patients with wheat allergy or sensitization undergo serial oral challenges to wheat at least every two years, in the absence of an interval history of symptoms triggered by an exposure. Additional variables to take into consideration before proceeding with the challenge include the wheat-specific IgE level and how it compares to the level at the time of the last challenge, the result of the last challenge (eg, did the reaction occur at the beginning or near the end of the challenge and what was the severity of the reaction?), and the age of the child (eg, resolution may occur at later ages, but is more likely to occur in a two-year time span in a younger child).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Soy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend repeat evaluation yearly with CAP-FEIA testing. These allergies are generally outgrown more quickly than those to egg or milk. Challenge can be offered when the results of in vitro testing have reached low levels, although these are not as well defined as for the previous foods, and the situation is probably similar to that for wheat.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Other foods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Yearly in vitro testing is our general recommendation. As mentioned previously, repeat evaluation can be less frequent with time if there is minimal evidence of improvement over several years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY OF SPECIFIC ALLERGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues relating to prevalence, resolution, and recurrences of food allergy are best understood with respect to the specific food. The most reliable information concerns allergies to cow's milk, hen's egg,",
"    <span class=\"nowrap\">",
"     peanut/tree",
"    </span>",
"    nuts, and wheat. The natural history of other food allergies, such as allergies to soy and sesame, has been less well studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cow's milk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cow's milk allergy (CMA) is the most common food allergy among infants and young children. Resolution is gradual throughout childhood and adolescence, and is influenced by various factors.",
"   </p>",
"   <p>",
"    Up to 50 percent of children with CMA also have concomitant adverse reactions to other foods [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, 50 to 80 percent have allergic rhinitis and asthma in response to inhaled environmental allergens by puberty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMA affects approximately 2.5 percent of children during the first two years of life [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/6,15,36\">",
"     6,15,36",
"    </a>",
"    ]. One of the best studies of CMA prevalence is the large prospective Danish study reviewed previously [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/15\">",
"     15",
"    </a>",
"    ]. Cow's milk allergy was confirmed in 2.2 percent of children followed from birth through age three years. Of note, nearly one-half of these cases were non-IgE-mediated allergic conditions, such as dietary protein-induced",
"    <span class=\"nowrap\">",
"     proctitis/colitis,",
"    </span>",
"    enteropathy, and enterocolitis. The estimated overall prevalence in the United States in a national survey was 0.4 percent, based upon serologic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Resolution",
"    </span>",
"    &nbsp;&mdash;&nbsp;The resolution of CMA is variable, depending upon the type of allergy (IgE-mediated or non-IgE-mediated) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/15,30,36\">",
"     15,30,36",
"    </a>",
"    ] and the population examined (general public or referral populations) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/15,25,37\">",
"     15,25,37",
"    </a>",
"    ]. Concomitant allergic rhinitis and asthma and onset of the allergy at &lt;1 month of age may also be risk factors for persistent food allergies.",
"   </p>",
"   <p>",
"    Resolution rates for IgE-mediated CMA are significantly lower than those of non-IgE-mediated milk allergy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study followed 98 children (median age 24 months) with CMA for a median of two years (range: 6 to 72 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/30\">",
"       30",
"      </a>",
"      ]. Twenty-two percent of those with IgE-mediated allergy (representing approximately two-thirds of the total group) became tolerant, whereas 59 percent of those with non-IgE-mediated CMA became tolerant.",
"     </li>",
"     <li>",
"      Another study followed 139 children with CMA (aged 14 months to 18 years at the end of the study) for an average of seven years [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/38\">",
"       38",
"      </a>",
"      ]. Sixty-six of the children had IgE-mediated CMA. In the whole group, CMA resolved in 34 percent by age two years, 55 percent by age five, and 68 percent by age 10. However, tolerance was delayed in the subgroup of children with IgE-mediated CMA, with resolution occurring in none of these children by age two years, 22 percent by age five, and 43 percent by age 10.",
"     </li>",
"     <li>",
"      In the Danish study previously described, 76 percent of those with IgE-mediated allergy had become cow's milk tolerant, and 100 percent of those with non-IgE-mediated allergy were tolerant by age three years [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/15\">",
"       15",
"      </a>",
"      ]. Of note, these rates of resolution were much higher than those in subsequent studies, and may be due to the recruitment of affected children from the general population, in whom the range of disease severity is likely to be broad.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Resolution rates vary in different study populations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rates of resolution in children with IgE-mediated CMA followed in allergy practices are lower than those of children in the general population, probably because these children are more severely allergic, although other confounders have not been excluded. One large retrospective study reported resolution rates in 807 children with CMA who were followed by allergy specialists [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/25\">",
"       25",
"      </a>",
"      ]. If resolution was defined as passing a challenge procedure or having a cow's milk-specific IgE (CM-IgE) of &lt;3",
"      <span class=\"nowrap\">",
"       kUA/L",
"      </span>",
"      and no reactions within the past year, CMA resolved in 19, 42, 64, and 79 percent of children at ages 4, 8, 12, and 16 years, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Finally, several clinical features are associated with persistent IgE-mediated CMA, including the presence of concomitant allergic rhinitis or asthma and onset of the allergy in the first month of life [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/25,37,39\">",
"     25,37,39",
"    </a>",
"    ]. As an example, an Israeli study followed 105 children with cow's milk allergy for a period of eight years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/39\">",
"     39",
"    </a>",
"    ]. Sixty-one percent of patients with persistent CMA had asthma, compared to 19 percent in the resolution group. However, this association may just reflect the fact that these children were followed later into childhood than children whose allergy had resolved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Milk-specific IgE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the higher the CM-IgE, the less likely the child is to become tolerant over time. In the retrospective study discussed previously, persistence was more likely in patients with higher initial levels of CM-IgE. Median CM-IgE in the first two years of life was 19",
"    <span class=\"nowrap\">",
"     kUA/L",
"    </span>",
"    in the children with CMA that persisted, compared to 1.8",
"    <span class=\"nowrap\">",
"     kUA/L",
"    </span>",
"    in those with CMA that eventually resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, CM-IgE levels in persistent CMA tended to increase over the first three to four years of life and then gradually decrease, while those in resolving CMA were stable initially and then gradually declined (",
"    <a class=\"graphic graphic_figure graphicRef73825 \" href=\"UTD.htm?18/6/18530\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Another study examined the rate of change in levels of CM-IgE over time, in relation to the patient's age, in children who developed CMA before the age of four years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/40\">",
"     40",
"    </a>",
"    ]. CM-IgE levels decreased more rapidly in those who developed tolerance. Independent of initial levels, the percentage amount that CM-IgE dropped in one year correlated with the likelihood that the child would pass a food challenge performed at that time. If the CM-IgE dropped 50, 75, 90, and 99 percent, there was a 31, 45, 66, and 95 percent chance of passing challenge, respectively.",
"   </p>",
"   <p>",
"    IgE molecules are not equally pathogenic, and IgE directed against certain types of epitopes may be associated with persistent allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. However, the food-specific IgE tests that are currently available commercially do not distinguish among IgE molecules directed toward different epitopes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IgE- and IgG-binding epitopes on alpha-s1-casein (a significant milk allergen) were identified using the sera of 24 cow's milk-allergic children [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/41\">",
"       41",
"      </a>",
"      ]. Epitope recognition patterns in older children with persistent milk allergy were compared to those in younger children who were likely to outgrow their allergy. Although there were no differences in binding of IgG between the two groups, two IgE-binding regions were recognized by the majority of the older children with persistent allergy, but none of the younger children.",
"     </li>",
"     <li>",
"      A similar analysis was performed in subsequent studies of IgE- and IgG-binding epitopes on beta- and kappa-casein in cow's milk-allergic patients [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/42,44\">",
"       42,44",
"      </a>",
"      ]. Three IgE-binding regions on beta-casein and six on kappa-casein were recognized by patients with persistent cow's milk allergy, but not by those with transient allergy.",
"     </li>",
"     <li>",
"      A third study found that patients with persistent cow's milk allergy had higher levels of IgE to linear (primary sequence) epitopes (rather than tertiary or conformational epitopes) from alpha-s1-casein and beta-casein than children who achieved tolerance [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Such data may lead to new clinical tests, such as epitope-specific RASTs, that will permit the identification of children who are at risk for persistent cow's milk allergy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMA affects 2 to 3 percent of children during the first two years of life. Observations concerning CMA resolution include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non&ndash;IgE-mediated CMA appears to be a transient childhood condition, which is almost always outgrown. By comparison, IgE-mediated CMA may persist through adolescence and beyond.",
"     </li>",
"     <li>",
"      In counseling patients and families, the pediatrician treating the general population can expect high rates of resolution, whereas allergy specialists with referred patient populations should anticipate lower resolution rates.",
"     </li>",
"     <li>",
"      Children with IgE-mediated CMA and higher peak CM-IgE levels tend to have more persistent disease.",
"     </li>",
"     <li>",
"      Children with allergic rhinitis or asthma are more likely to have IgE-mediated CMA that persists.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Hen's egg",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hen's egg allergy is one of the most common food allergies of childhood, and like cow's milk allergy, it is frequently outgrown during childhood or adolescence. The presence of egg allergy is a marker for subsequent sensitization to aeroallergens, as well as the later development of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/12,45\">",
"     12,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Egg allergy affects 1 to 2 percent of young children [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/2,11\">",
"     2,11",
"    </a>",
"    ]. The estimated overall prevalence in the United States in a national survey was 0.2 percent, based upon serologic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/3\">",
"     3",
"    </a>",
"    ]. Most reactions are IgE-mediated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Resolution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergy to egg usually resolves within several years of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/18,40,46,47\">",
"     18,40,46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of resolution of egg allergy was estimated in one prospective study that followed 58 children, beginning at ages younger than two years [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/47\">",
"       47",
"      </a>",
"      ]. One-half of children became tolerant by 35 months of follow-up (4 to 4.5 years old), and two-thirds became tolerant by five years of follow-up.",
"     </li>",
"     <li>",
"      A retrospective study of 881 children with egg allergy followed by allergy specialists found that resolution was slower in this referral population [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/24\">",
"       24",
"      </a>",
"      ]. When resolution was defined as passing a challenge procedure involving the ingestion of one whole cooked egg, egg allergy resolved in 4, 26, 48, and 68 percent of children at ages 4, 8, 12, and 16 years, respectively. An egg-specific IgE (E-IgE) level &ge;50",
"      <span class=\"nowrap\">",
"       kUA/L",
"      </span>",
"      was a marker of persistent egg allergy in this study population.",
"     </li>",
"     <li>",
"      Tolerance to egg in baked goods is common and typically occurs at an earlier age than tolerance to lightly cooked or raw egg [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/24,48-50\">",
"       24,48-50",
"      </a>",
"      ]. In one series of children with egg allergy, the median age of tolerance to well-cooked egg was 5.6 years versus a median of 10.3 years for uncooked egg [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Egg-specific IgE levels decreased more rapidly in those children who developed tolerance than in those with persistent allergy, as with cow's milk allergy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/40\">",
"       40",
"      </a>",
"      ]. In a group of children who developed food allergy before the age of four, the percentage amount that E-IgE dropped in one year correlated with the likelihood that the child would pass a food challenge performed at that time. If the E-IgE dropped 50, 75, 90, and 99 percent, there was a 52, 65, 78, and 95 percent chance of passing challenge, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Egg allergy appears to affect between 1 and 2 percent of the pediatric population. The majority of cases resolve within childhood or adolescence. As with cow's milk allergy, the rate at which egg-specific IgE levels decrease can be used to assess the likelihood that a child has outgrown the sensitivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Peanut and tree nut",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peanut and tree nut allergies are frequently studied together as they coexist in up to 30 to 40 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. More information is available on the natural history of peanut allergy, and the understanding of it is changing. Although it was initially believed to be a lifelong sensitivity in nearly all cases, subsequent studies have shown that tolerance can develop in approximately 20 to 25 percent of patients. Less is known about tree nut allergy, although a minority of patients appear to lose this sensitivity as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cumulative findings of several studies from the United States and Europe in the late 1990s and early 2000s estimated the prevalence of peanut and tree nut allergies at 0.4 to 1.3 percent in children and 0.5 to 1 percent in the overall population [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/51,52,54-57\">",
"     51,52,54-57",
"    </a>",
"    ]. As an example, sensitization and clinical reactivity to peanut and tree nuts were studied in a cohort of children on the Isle of Wight [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/58\">",
"     58",
"    </a>",
"    ]. All children born during a single year were recruited and followed prospectively. By four years of age, 15 of the 1218 participating children (1.2 percent) developed positive skin prick tests to peanut or tree nuts, and approximately half of these (0.5 percent) had allergic reactions upon ingestion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38457?source=see_link\">",
"     \"Peanut, tree nut, and seed allergy: Clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serial studies in the United Kingdom and the United States have suggested that the prevalence of peanut allergy is increasing over time [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/52,56,59\">",
"     52,56,59",
"    </a>",
"    ]. In a random calling telephone survey conducted in the United States, the reported prevalence of peanut allergy in children increased from 0.4 in 1997 to 0.8 percent in 2002 and 1.4 percent in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/52,60\">",
"     52,60",
"    </a>",
"    ]. The estimated overall prevalence in the United States in a national 2005-2006 survey was 1.3 percent, based upon serologic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/3\">",
"     3",
"    </a>",
"    ]. The age of onset also appears to be changing, with the diagnosis being made in progressively younger children [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Resolution",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peanut &mdash; Early studies of peanut allergy suggested that it was persistent [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/62\">",
"       62",
"      </a>",
"      ]; however, it is now realized that up to one-quarter of patients become tolerant over time [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/53,55,63,64\">",
"       53,55,63,64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One of the first studies to demonstrate resolution evaluated 230 children with a diagnosis of peanut allergy and performed oral challenges in 120 [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/63\">",
"       63",
"      </a>",
"      ]. Those with a negative skin prick test or a history of tolerating peanut were offered a challenge and those with a history of life-threatening reactions were not, so the selection of patients challenged was not randomized. A total of 22 children between the ages of two and nine years had a negative challenge (9.8 percent of the total group). A negative challenge was associated with a smaller-sized skin prick test reaction and fewer allergies to other foods.",
"     </li>",
"     <li>",
"      A later study by our group, which demonstrated a rate of resolution of 21.5 percent, evaluated 223 children with the diagnosis of peanut allergy, and included oral challenge in 85 children who had not had a reaction in the past year and who had a (peanut specific-IgE) PN-IgE &lt;20",
"      <span class=\"nowrap\">",
"       kUA/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/53\">",
"       53",
"      </a>",
"      ]. Children with either a history of a recent reaction or a PN-IgE level &gt;20",
"      <span class=\"nowrap\">",
"       kUA/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/33\">",
"       33",
"      </a>",
"      ] were considered still allergic and not offered challenge, and an additional 41 children were eligible for challenge but declined. Of the 85 children challenged, 48 (21.5 percent of the total group) passed the challenge and were believed to have outgrown their peanut allergy. Four additional children passed challenges after the study was completed, increasing the rate of resolution to 23.3 percent.",
"     </li>",
"     <li>",
"      In a second similar study by our group, 80 peanut allergic children underwent evaluation and challenge (either open or DBPCFC) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/55\">",
"       55",
"      </a>",
"      ]. All were four years of age or older and had PN-IgE levels &le;5",
"      <span class=\"nowrap\">",
"       kUA/L",
"      </span>",
"      at the time of challenge. Upon challenge, 55 percent of patients tolerated peanut overall. Sixty-three percent of children with PN-IgE levels &le;2",
"      <span class=\"nowrap\">",
"       kUA/L,",
"      </span>",
"      and 73 percent with negative PN-IgE levels passed. It was notable, however, that eight patients with PN-IgE levels &le;0.35",
"      <span class=\"nowrap\">",
"       kUA/L",
"      </span>",
"      failed challenge.",
"      <br/>",
"      <br/>",
"      Subsequent dietary behaviors and recurrent reactions were then evaluated by our group using a telephone questionnaire in all patients who passed DBPCFC (ie, tolerated peanut) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/53,55\">",
"       53,55",
"      </a>",
"      ]. Of the 64 patients who passed challenges, 97 percent subsequently ate peanut, but most did so infrequently, ie, once a month or less. There were two possible cases of recurrent reactions. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Recurrence'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Tree nut &mdash; Few data exist concerning the resolution of tree nut allergy. In one study that used DBPCFC to confirm the loss of clinical reactivity, the resolution of tree nut allergy was estimated to be at least 9 percent (9 of 101 children) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/65\">",
"       65",
"      </a>",
"      ]. The rate of resolution increased with lower TN-IgE levels (58, 63, and 75 percent of children with TN-IgE levels &lt;5",
"      <span class=\"nowrap\">",
"       kUA/L,",
"      </span>",
"      &lt;2",
"      <span class=\"nowrap\">",
"       kUA/L,",
"      </span>",
"      and negative TN-IgE levels, respectively).",
"      <br/>",
"      <br/>",
"      Factors that did",
"      <strong>",
"       not",
"      </strong>",
"      predict the development of tolerance included the severity of the initial reaction and the history of having outgrown other food allergies other than peanut. In contrast, patients who had outgrown peanut allergy were more likely to outgrow tree nut allergy. No child that had reactions to more than two different tree nuts achieved tolerance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of serial objective testing appear to be the best indicator of resolution or persistence of nut allergy. An Australian study of 267 children referred to a specialty center and diagnosed with peanut allergy before the age of two years investigated the clinical and laboratory predictors of resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/64\">",
"     64",
"    </a>",
"    ]. A diameter of positive skin prick test wheal &ge;6 mm or a PN-IgE &ge;3",
"    <span class=\"nowrap\">",
"     kUA/L",
"    </span>",
"    before the age of two were found to be independent predictors of persistent allergy at age eight years in this population (although these values may not apply to other pediatric populations). Patients whose allergy eventually resolved tended to have positive skin tests of decreasing size between ages one and four years, while patients with persistent allergy typically had increasingly larger positive skin tests. In contrast, this and other studies found that clinical features did not reliably predict persistence; neither the presence of other atopic diseases, age at diagnosis, nor the severity of initial peanut or tree nut reactions predicted subsequent loss of the allergy. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Monitoring the food-allergic child'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Studies evaluating the resolution of both peanut and tree nut allergy also suggest the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low or undetectable specific IgE levels, as measured by CAP-RAST (or CAP-FEIA), were the best predictors of a negative challenge.",
"     </li>",
"     <li>",
"      Challenge was essential to determine the loss of allergy with certainty, as some patients still reacted even when their skin prick tests",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      CAP-RASTs became completely negative. It has been our estimation that this may occur in as many as 10 percent of patients in such studies.",
"     </li>",
"     <li>",
"      Tolerance of peanut does not imply tolerance of tree nuts or seeds. In patients who outgrow peanut allergy, tree nut allergy or seed allergy can persist or subsequently develop for the first time [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/66\">",
"       66",
"      </a>",
"      ]. Potential allergy to these foods must be independently evaluated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, recurrent reactions have been reported in patients thought to have outgrown peanut allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/53,55\">",
"     53,55",
"    </a>",
"    ]. In a third study by our group, recurrent reactions were found in 3 of 36 patients (8 percent) with a clear history of peanut allergy who had previously passed a peanut challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/67\">",
"     67",
"    </a>",
"    ]. An example of a case was a six-year-old girl who had presented at age one year with generalized urticaria and facial angioedema within five minutes of eating a peanut butter cracker. Her PN-IgE level at diagnosis was 2.79",
"    <span class=\"nowrap\">",
"     kUA/L,",
"    </span>",
"    and she had no history of other food allergies. At age 4.5 years her PN-IgE level was 1.1",
"    <span class=\"nowrap\">",
"     kUA/L",
"    </span>",
"    and she passed peanut challenge. She subsequently ate only \"may contain peanut\" products until approximately 1.8 years after the initial challenge, when she had two bites of Butterfinger ice cream and within 15 minutes developed urticaria, coughing, difficulty breathing, throat tightness, abdominal pain, vomiting, and diarrhea. A repeat PN-IgE level was &gt;100",
"    <span class=\"nowrap\">",
"     kUA/L.",
"    </span>",
"    A SPT was not performed, and a DBPCFC was deferred because of the severity of the reaction and the high PN-IgE level.",
"   </p>",
"   <p>",
"    In this and several other small series of patients with resolved peanut allergy, it appears that recurrence may be more common among those who continue to avoid peanut or eat it infrequently [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/53,55,67,68\">",
"     53,55,67,68",
"    </a>",
"    ]. In the study previously discussed, each of the three patients with recurrent allergy consumed concentrated peanut products less than once a month [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/67\">",
"     67",
"    </a>",
"    ]. In contrast, none of a group of 23 patients who ate peanut more frequently had recurrent allergy. Thus, infrequent exposure may be a risk factor for resensitization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peanut and tree nut allergy affects at least 0.5 to 1.4 percent of children and 0.5 to 1 percent of the general population, and may be increasing over time. This type of allergy is likely to be a lifelong disorder for most but not all patients. Because a substantial minority (ie, 20 to 25 percent for peanut and 9 percent for tree nut) of patients lose their sensitivity over time, it is appropriate to reevaluate children on a regular basis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have not had reactions in the past one to two years and who have low TN- or PN-IgE levels (&le;2",
"      <span class=\"nowrap\">",
"       kUA/L)",
"      </span>",
"      should be considered for an oral peanut challenge in a supervised setting. In our clinic, we obtain CAP-FEIA values yearly, and because of safety concerns, only challenge children older than four years of age. A negative CAP-FEIA is not a guarantee that the allergy is resolved, and challenge is necessary to make this determination.",
"     </li>",
"     <li>",
"      Peanut allergy can recur following resolution, although this is unusual. Tree nut allergy has not been studied as well. Infrequent ingestion of peanut may be a risk factor for recurrence, but these data are derived from small numbers of cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Wheat allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wheat allergy is also a common childhood food allergy that is usually outgrown by adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/35,69,70\">",
"     35,69,70",
"    </a>",
"    ]. Concomitant atopic disease and other food allergies are frequently seen [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Wheat allergy related to occupational exposure in adults is discussed separately, as is celiac disease (gluten-sensitive enteropathy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38776?source=see_link\">",
"     \"Respiratory manifestations of food allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7929?source=see_link\">",
"     \"Management of celiac disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgE-mediated wheat allergy has been reported to affect 0.4 to 1 percent of children in the United States (US) and the United Kingdom (UK), where wheat is a staple in the diet [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/7,71\">",
"     7,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Resolution",
"    </span>",
"    &nbsp;&mdash;&nbsp;In studies of children with food allergy and atopic dermatitis, wheat allergy was outgrown in 25 and 33 percent of children over a one and two year follow-up, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/19,72\">",
"     19,72",
"    </a>",
"    ]. In the general population, wheat allergy resolves in 80 percent of patients by five years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/69\">",
"     69",
"    </a>",
"    ]. However, tolerance appears to develop more slowly in a highly atopic population followed at a tertiary care center, as is seen in similar populations with cow's milk and hen's egg allergies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study examined the natural course of IgE-mediated wheat allergy in 103 children followed at a large referral center from 1993 to 2007 [",
"      <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/35\">",
"       35",
"      </a>",
"      ]. Oral challenges to wheat were performed in 61 percent during the study period. The median age at which tolerance was acquired was 6.6 years. However, the median age at resolution varied considerably depending upon peak wheat IgE (approximately 2, 4, and 10 years of age for children with peak wheat IgE levels &lt;20, 20 to 50, and &gt;50",
"      <span class=\"nowrap\">",
"       kU/L,",
"      </span>",
"      respectively). Overall, tolerance was achieved by 29, 56, and 70 percent at 4, 8, and 14 years of age, respectively. In children aged two to eight years, the median wheat IgE levels associated with resolved allergy ranged from 21 to 25",
"      <span class=\"nowrap\">",
"       kU/L,",
"      </span>",
"      whereas the median levels associated with persistent allergy ranged from 62 to 70",
"      <span class=\"nowrap\">",
"       kU/L.",
"      </span>",
"      Patients with wheat sensitization (wheat IgE &gt;20",
"      <span class=\"nowrap\">",
"       kU/L,",
"      </span>",
"      but no history of symptomatic exposure) passed challenges at rates similar to the children discussed above who had a history of symptomatic wheat allergy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgE-mediated wheat allergy affects 0.4 to 1 percent of the pediatric population. The majority of cases resolve by adolescence.",
"   </p>",
"   <p>",
"    The pediatrician treating the general population can expect high rates of resolution, whereas allergy specialists with referred patient populations should anticipate lower resolution rates. We suggest serial oral challenges to wheat at least every two years, regardless of specific IgE level, in the absence of an interval history of symptoms triggered by an exposure (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Wheat'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Other foods",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of other food allergies is less well studied.",
"   </p>",
"   <p>",
"    Earlier studies suggested that soy allergy is typically outgrown in the preschool-age years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/15,19,72,73\">",
"     15,19,72,73",
"    </a>",
"    ]. However, a subsequent larger retrospective study performed at a tertiary referral clinic found that only about 50 percent of children had outgrown soy allergy by seven years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/74\">",
"     74",
"    </a>",
"    ]. Soy allergy resolved in 25, 45, and 69 percent by age 4, 6, and 10 years, respectively.",
"   </p>",
"   <p>",
"    The limited data available suggests that sesame allergy, similar to peanut and tree nut allergies, is more likely to persist [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. The reported rate of resolution of sesame allergy ranges from 20 to 30 percent.",
"   </p>",
"   <p>",
"    As mentioned previously, adverse reactions to fruits, vegetables, and other cereal grains are typically very short-lived in children [",
"    <a class=\"abstract\" href=\"UTD.htm?12/28/12746/abstract/18,73,78\">",
"     18,73,78",
"    </a>",
"    ]. Many of these reactions may represent intolerances or irritant reactions rather than true allergy, and most children will lose their sensitivity to these foods within a period of 6 to 12 months. A minority of children have severe, IgE-mediated allergies to these foods that may persist over time, however.",
"   </p>",
"   <p>",
"    There are few studies addressing the natural history of seafood (fish and shellfish) allergies. These can develop in childhood, although adult onset is believed to be more common. Seafood allergies are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/61/16346?source=see_link\">",
"     \"Seafood allergies: Fish and shellfish\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/35/35379?source=see_link\">",
"       \"Patient information: Food allergy treatment and avoidance (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peak prevalence of food allergy is approximately 6 to 8 percent at one year of age and then falls progressively. By late childhood, the prevalence is 2 to 4 percent and remains stable thereafter. Food-allergic children are at high risk for developing later allergic rhinitis and asthma. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Prevalence of childhood food allergy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Resolution of selected food allergies",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most childhood food allergies are lost over during childhood or adolescence, although certain allergies tend to persist, such as those to",
"      <span class=\"nowrap\">",
"       fish/shellfish",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       peanut/tree",
"      </span>",
"      nut. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Overview of resolution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cow's milk allergy (all types) affects approximately 2.5 percent of children under two years of age. Non&ndash;IgE-mediated milk allergy is a transient childhood condition that is almost always outgrown, but must be managed carefully as challenge can be hazardous. IgE-mediated milk allergy may persist into adolescence, although it is usually outgrown by adulthood. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Cow's milk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Egg allergy affects 1 to 2 percent of children. The majority of cases resolve by adulthood. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Hen's egg'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peanut and tree nut allergies affect about 0.5 to 1.4 percent of children and may be increasing over time. It is likely to be a lifelong disorder for most patients, although 20 to 25 percent outgrow peanut and at least 9 percent outgrow tree nut allergies. Recurrence is rare, although a few cases have been documented. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Peanut and tree nut'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Monitoring and testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal monitoring of the food-allergic child requires the cooperative input of both the general pediatrician (to assess growth and development) and the allergist (to address ongoing education, proper medication use, and reevaluate allergic status). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Monitoring the food-allergic child'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most allergy experts use a combination of historical information from accidental exposures and periodic in vitro",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      skin testing. As an example, a challenge may be offered at a higher specific IgE level if there is a history of a recent accidental exposure without a reaction. Alternatively, a challenge will not be offered when the specific IgE is below the designated cutoff level if the patient has had a recent exposure that triggered a reaction. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Serial testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medically supervised food challenge is recommended to confirm that a food allergy has resolved, as in vitro and skin tests can remain positive in patients who achieve clinical tolerance, and conversely, tests can become negative in patients who still react upon ingestion, although the latter situation is uncommon. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Determining if an allergy has resolved'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For IgE-mediated cow's milk allergy, we repeat milk-specific CAP-FEIA testing yearly and offer challenge when the level is &le;2",
"      <span class=\"nowrap\">",
"       kUA/L.",
"      </span>",
"      At this level, the pass rate is approximately 50 percent. However, performance of challenges to extensively heated (baked) milk should be considered on an individual basis, since many patients with higher IgE levels may tolerate milk protein in this form. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Cow's milk and egg'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40087?source=see_link&amp;anchor=H9#H9\">",
"       \"Milk allergy: Management\", section on 'Clinical scenarios'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For IgE-mediated egg allergy, we repeat egg-specific CAP-FEIA testing yearly and offer challenge when the specific IgE level is &le;2",
"      <span class=\"nowrap\">",
"       kUA/L.",
"      </span>",
"      At this level, the pass rate is approximately 50 percent. However, as with milk allergy, many patients with higher IgE levels may tolerate extensively heated (baked) egg. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Cow's milk and egg'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13223?source=see_link&amp;anchor=H7#H7\">",
"       \"Egg allergy: Management\", section on 'Clinical scenarios'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with peanut or tree nut allergy who are over four years of age and have not had reactions in the past one to two years and who have specific CAP-FEIA values &le;2",
"      <span class=\"nowrap\">",
"       kUA/L",
"      </span>",
"      should be offered challenge in a supervised setting. At this level the pass rate is approximately 60 percent. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Peanut or tree nut'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/1\">",
"      Osborne NJ, Koplin JJ, Martin PE, et al. Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants. J Allergy Clin Immunol 2011; 127:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/2\">",
"      Sicherer SH, Sampson HA. 9. Food allergy. J Allergy Clin Immunol 2006; 117:S470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/3\">",
"      Liu AH, Jaramillo R, Sicherer SH, et al. National prevalence and risk factors for food allergy and relationship to asthma: results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol 2010; 126:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/4\">",
"      Branum AM, Lukacs SL. Food allergy among children in the United States. Pediatrics 2009; 124:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/5\">",
"      Eggesb&oslash; M, Halvorsen R, Tambs K, Botten G. Prevalence of parentally perceived adverse reactions to food in young children. Pediatr Allergy Immunol 1999; 10:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/6\">",
"      Eggesb&oslash; M, Botten G, Halvorsen R, Magnus P. The prevalence of CMA/CMPI in young children: the validity of parentally perceived reactions in a population-based study. Allergy 2001; 56:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/7\">",
"      Venter C, Pereira B, Grundy J, et al. Incidence of parentally reported and clinically diagnosed food hypersensitivity in the first year of life. J Allergy Clin Immunol 2006; 117:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/8\">",
"      Pyrh&ouml;nen K, N&auml;yh&auml; S, Kaila M, et al. Occurrence of parent-reported food hypersensitivities and food allergies among children aged 1-4 yr. Pediatr Allergy Immunol 2009; 20:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/9\">",
"      Leung TF, Yung E, Wong YS, et al. Parent-reported adverse food reactions in Hong Kong Chinese pre-schoolers: epidemiology, clinical spectrum and risk factors. Pediatr Allergy Immunol 2009; 20:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/10\">",
"      McBride D, Keil T, Grabenhenrich L, et al. The EuroPrevall birth cohort study on food allergy: baseline characteristics of 12,000 newborns and their families from nine European countries. Pediatr Allergy Immunol 2012; 23:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/11\">",
"      Eggesb&oslash; M, Botten G, Halvorsen R, Magnus P. The prevalence of allergy to egg: a population-based study in young children. Allergy 2001; 56:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/12\">",
"      Nickel R, Kulig M, Forster J, et al. Sensitization to hen's egg at the age of twelve months is predictive for allergic sensitization to common indoor and outdoor allergens at the age of three years. J Allergy Clin Immunol 1997; 99:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/13\">",
"      Kulig M, Bergmann R, Niggemann B, et al. Prediction of sensitization to inhalant allergens in childhood: evaluating family history, atopic dermatitis and sensitization to food allergens. The MAS Study Group. Multicentre Allergy Study. Clin Exp Allergy 1998; 28:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/14\">",
"      Kulig M, Bergmann R, Klettke U, et al. Natural course of sensitization to food and inhalant allergens during the first 6 years of life. J Allergy Clin Immunol 1999; 103:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/15\">",
"      H&oslash;st A, Halken S. A prospective study of cow milk allergy in Danish infants during the first 3 years of life. Clinical course in relation to clinical and immunological type of hypersensitivity reaction. Allergy 1990; 45:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/16\">",
"      Hattevig G, Kjellman B, Johansson SG, Bj&ouml;rkst&eacute;n B. Clinical symptoms and IgE responses to common food proteins in atopic and healthy children. Clin Allergy 1984; 14:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/17\">",
"      Sigurs N, Hattevig G, Kjellman B, et al. Appearance of atopic disease in relation to serum IgE antibodies in children followed up from birth for 4 to 15 years. J Allergy Clin Immunol 1994; 94:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/18\">",
"      Dannaeus A, Ingan&auml;s M. A follow-up study of children with food allergy. Clinical course in relation to serum IgE- and IgG-antibody levels to milk, egg and fish. Clin Allergy 1981; 11:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/19\">",
"      Sampson HA, Scanlon SM. Natural history of food hypersensitivity in children with atopic dermatitis. J Pediatr 1989; 115:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/20\">",
"      James JM, Sampson HA. Immunologic changes associated with the development of tolerance in children with cow milk allergy. J Pediatr 1992; 121:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/21\">",
"      Pastorello EA, Stocchi L, Pravettoni V, et al. Role of the elimination diet in adults with food allergy. J Allergy Clin Immunol 1989; 84:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/22\">",
"      Allen CW, Kemp AS, Campbell DE. Dietary advice, dietary adherence and the acquisition of tolerance in egg-allergic children: a 5-yr follow-up. Pediatr Allergy Immunol 2009; 20:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/23\">",
"      Taylor SL, Hefle SL, Bindslev-Jensen C, et al. A consensus protocol for the determination of the threshold doses for allergenic foods: how much is too much? Clin Exp Allergy 2004; 34:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/24\">",
"      Savage JH, Matsui EC, Skripak JM, Wood RA. The natural history of egg allergy. J Allergy Clin Immunol 2007; 120:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/25\">",
"      Skripak JM, Matsui EC, Mudd K, Wood RA. The natural history of IgE-mediated cow's milk allergy. J Allergy Clin Immunol 2007; 120:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/26\">",
"      Lieberman JA, Huang FR, Sampson HA, Nowak-W��grzyn A. Outcomes of 100 consecutive open, baked-egg oral food challenges in the allergy office. J Allergy Clin Immunol 2012; 129:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/27\">",
"      Larramendi CH, Mart&iacute;n Esteban M, Pascual Marcos C, et al. Possible consequences of elimination diets in asymptomatic immediate hypersensitivity to fish. Allergy 1992; 47:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/28\">",
"      Flinterman AE, Knulst AC, Meijer Y, et al. Acute allergic reactions in children with AEDS after prolonged cow's milk elimination diets. Allergy 2006; 61:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/29\">",
"      David TJ. Anaphylactic shock during elimination diets for severe atopic eczema. Arch Dis Child 1984; 59:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/30\">",
"      Hill DJ, Firer MA, Ball G, Hosking CS. Natural history of cows' milk allergy in children: immunological outcome over 2 years. Clin Exp Allergy 1993; 23:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/31\">",
"      Perry TT, Matsui EC, Kay Conover-Walker M, Wood RA. The relationship of allergen-specific IgE levels and oral food challenge outcome. J Allergy Clin Immunol 2004; 114:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/32\">",
"      Di&eacute;guez MC, Cerecedo I, Muriel A, et al. Utility of diagnostic tests in the follow-up of egg-allergic children. Clin Exp Allergy 2009; 39:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/33\">",
"      Sampson HA, Ho DG. Relationship between food-specific IgE concentrations and the risk of positive food challenges in children and adolescents. J Allergy Clin Immunol 1997; 100:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/34\">",
"      Sampson HA. Utility of food-specific IgE concentrations in predicting symptomatic food allergy. J Allergy Clin Immunol 2001; 107:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/35\">",
"      Keet CA, Matsui EC, Dhillon G, et al. The natural history of wheat allergy. Ann Allergy Asthma Immunol 2009; 102:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/36\">",
"      H&oslash;st A. Frequency of cow's milk allergy in childhood. Ann Allergy Asthma Immunol 2002; 89:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/37\">",
"      Elizur A, Rajuan N, Goldberg MR, et al. Natural course and risk factors for persistence of IgE-mediated cow's milk allergy. J Pediatr 2012; 161:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/38\">",
"      Santos A, Dias A, Pinheiro JA. Predictive factors for the persistence of cow's milk allergy. Pediatr Allergy Immunol 2010; 21:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/39\">",
"      Levy Y, Segal N, Garty B, Danon YL. Lessons from the clinical course of IgE-mediated cow milk allergy in Israel. Pediatr Allergy Immunol 2007; 18:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/40\">",
"      Shek LP, Soderstrom L, Ahlstedt S, et al. Determination of food specific IgE levels over time can predict the development of tolerance in cow's milk and hen's egg allergy. J Allergy Clin Immunol 2004; 114:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/41\">",
"      Chatchatee P, J&auml;rvinen KM, Bardina L, et al. Identification of IgE- and IgG-binding epitopes on alpha(s1)-casein: differences in patients with persistent and transient cow's milk allergy. J Allergy Clin Immunol 2001; 107:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/42\">",
"      Chatchatee P, J&auml;rvinen KM, Bardina L, et al. Identification of IgE and IgG binding epitopes on beta- and kappa-casein in cow's milk allergic patients. Clin Exp Allergy 2001; 31:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/43\">",
"      Vila L, Beyer K, J&auml;rvinen KM, et al. Role of conformational and linear epitopes in the achievement of tolerance in cow's milk allergy. Clin Exp Allergy 2001; 31:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/44\">",
"      J&auml;rvinen KM, Beyer K, Vila L, et al. B-cell epitopes as a screening instrument for persistent cow's milk allergy. J Allergy Clin Immunol 2002; 110:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/45\">",
"      Ricci G, Patrizi A, Baldi E, et al. Long-term follow-up of atopic dermatitis: retrospective analysis of related risk factors and association with concomitant allergic diseases. J Am Acad Dermatol 2006; 55:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/46\">",
"      Ford RP, Taylor B. Natural history of egg hypersensitivity. Arch Dis Child 1982; 57:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/47\">",
"      Boyano-Mart&iacute;nez T, Garc&iacute;a-Ara C, D&iacute;az-Pena JM, Mart&iacute;n-Esteban M. Prediction of tolerance on the basis of quantification of egg white-specific IgE antibodies in children with egg allergy. J Allergy Clin Immunol 2002; 110:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/48\">",
"      Des Roches A, Nguyen M, Paradis L, et al. Tolerance to cooked egg in an egg allergic population. Allergy 2006; 61:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/49\">",
"      Konstantinou GN, Giavi S, Kalobatsou A, et al. Consumption of heat-treated egg by children allergic or sensitized to egg can affect the natural course of egg allergy: hypothesis-generating observations. J Allergy Clin Immunol 2008; 122:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/50\">",
"      Clark A, Islam S, King Y, et al. A longitudinal study of resolution of allergy to well-cooked and uncooked egg. Clin Exp Allergy 2011; 41:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/51\">",
"      Sicherer SH, Mu&ntilde;oz-Furlong A, Burks AW, Sampson HA. Prevalence of peanut and tree nut allergy in the US determined by a random digit dial telephone survey. J Allergy Clin Immunol 1999; 103:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/52\">",
"      Sicherer SH, Mu&ntilde;oz-Furlong A, Sampson HA. Prevalence of peanut and tree nut allergy in the United States determined by means of a random digit dial telephone survey: a 5-year follow-up study. J Allergy Clin Immunol 2003; 112:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/53\">",
"      Skolnick HS, Conover-Walker MK, Koerner CB, et al. The natural history of peanut allergy. J Allergy Clin Immunol 2001; 107:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/54\">",
"      Emmett SE, Angus FJ, Fry JS, Lee PN. Perceived prevalence of peanut allergy in Great Britain and its association with other atopic conditions and with peanut allergy in other household members. Allergy 1999; 54:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/55\">",
"      Fleischer DM, Conover-Walker MK, Christie L, et al. The natural progression of peanut allergy: Resolution and the possibility of recurrence. J Allergy Clin Immunol 2003; 112:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/56\">",
"      Grundy J, Matthews S, Bateman B, et al. Rising prevalence of allergy to peanut in children: Data from 2 sequential cohorts. J Allergy Clin Immunol 2002; 110:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/57\">",
"      Kagan RS, Joseph L, Dufresne C, et al. Prevalence of peanut allergy in primary-school children in Montreal, Canada. J Allergy Clin Immunol 2003; 112:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/58\">",
"      Tariq SM, Stevens M, Matthews S, et al. Cohort study of peanut and tree nut sensitisation by age of 4 years. BMJ 1996; 313:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/59\">",
"      Hourihane JO, Aiken R, Briggs R, et al. The impact of government advice to pregnant mothers regarding peanut avoidance on the prevalence of peanut allergy in United Kingdom children at school entry. J Allergy Clin Immunol 2007; 119:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/60\">",
"      Sicherer SH, Mu&ntilde;oz-Furlong A, Godbold JH, Sampson HA. US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. J Allergy Clin Immunol 2010; 125:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/61\">",
"      Green TD, LaBelle VS, Steele PH, et al. Clinical characteristics of peanut-allergic children: recent changes. Pediatrics 2007; 120:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/62\">",
"      Bock SA, Atkins FM. The natural history of peanut allergy. J Allergy Clin Immunol 1989; 83:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/63\">",
"      Hourihane JO, Roberts SA, Warner JO. Resolution of peanut allergy: case-control study. BMJ 1998; 316:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/64\">",
"      Ho MH, Wong WH, Heine RG, et al. Early clinical predictors of remission of peanut allergy in children. J Allergy Clin Immunol 2008; 121:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/65\">",
"      Fleischer DM, Conover-Walker MK, Matsui EC, Wood RA. The natural history of tree nut allergy. J Allergy Clin Immunol 2005; 116:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/66\">",
"      Beausoleil JL, Spergel JM. Late diagnosis of tree nut and sesame allergy in patients previously sensitized but tolerant to peanut. Ann Allergy Asthma Immunol 2006; 97:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/67\">",
"      Fleischer DM, Conover-Walker MK, Christie L, et al. Peanut allergy: recurrence and its management. J Allergy Clin Immunol 2004; 114:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/68\">",
"      Busse PJ, Nowak-Wegrzyn AH, Noone SA, et al. Recurrent peanut allergy. N Engl J Med 2002; 347:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/69\">",
"      Lack G. Clinical practice. Food allergy. N Engl J Med 2008; 359:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/70\">",
"      Kotaniemi-Syrj&auml;nen A, Palosuo K, Jartti T, et al. The prognosis of wheat hypersensitivity in children. Pediatr Allergy Immunol 2010; 21:e421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/71\">",
"      Poole JA, Barriga K, Leung DY, et al. Timing of initial exposure to cereal grains and the risk of wheat allergy. Pediatrics 2006; 117:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/72\">",
"      Sampson HA, McCaskill CC. Food hypersensitivity and atopic dermatitis: evaluation of 113 patients. J Pediatr 1985; 107:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/73\">",
"      Bock SA. Prospective appraisal of complaints of adverse reactions to foods in children during the first 3 years of life. Pediatrics 1987; 79:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/74\">",
"      Savage JH, Kaeding AJ, Matsui EC, Wood RA. The natural history of soy allergy. J Allergy Clin Immunol 2010; 125:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/75\">",
"      Cohen A, Goldberg M, Levy B, et al. Sesame food allergy and sensitization in children: the natural history and long-term follow-up. Pediatr Allergy Immunol 2007; 18:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/76\">",
"      Aaronov D, Tasher D, Levine A, et al. Natural history of food allergy in infants and children in Israel. Ann Allergy Asthma Immunol 2008; 101:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/77\">",
"      Agne PS, Bidat E, Agne PS, et al. Sesame seed allergy in children. Eur Ann Allergy Clin Immunol 2004; 36:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/28/12746/abstract/78\">",
"      Kajosaari M. Food allergy in Finnish children aged 1 to 6 years. Acta Paediatr Scand 1982; 71:815.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5745 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-853D91569B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_28_12746=[""].join("\n");
var outline_f12_28_12746=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION OF FOOD ALLERGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREVALENCE OF CHILDHOOD FOOD ALLERGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OVERVIEW OF RESOLUTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Patterns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Role of avoidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MONITORING THE FOOD-ALLERGIC CHILD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Serial testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Determining if an allergy has resolved",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Cow's milk and egg",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Peanut or tree nut",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Wheat",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Soy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Other foods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      NATURAL HISTORY OF SPECIFIC ALLERGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cow's milk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Prevalence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Resolution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Milk-specific IgE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Hen's egg",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Prevalence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Resolution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Peanut and tree nut",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Prevalence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Resolution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Wheat allergy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Prevalence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Resolution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Other foods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Resolution of selected food allergies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Monitoring and testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5745\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5745|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/6/18530\" title=\"figure 1\">",
"      IgE trends in CMA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=related_link\">",
"      Clinical manifestations and diagnosis of celiac disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=related_link\">",
"      Clinical manifestations of food allergy: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13223?source=related_link\">",
"      Egg allergy: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=related_link\">",
"      Food protein-induced proctitis/colitis and enteropathy of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7929?source=related_link\">",
"      Management of celiac disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=related_link\">",
"      Management of food allergy: Avoidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40087?source=related_link\">",
"      Milk allergy: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=related_link\">",
"      Oral food challenges for diagnosis and management of food allergies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=related_link\">",
"      Overview of in vitro allergy tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/35/35379?source=related_link\">",
"      Patient information: Food allergy treatment and avoidance (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38457?source=related_link\">",
"      Peanut, tree nut, and seed allergy: Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38776?source=related_link\">",
"      Respiratory manifestations of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/61/16346?source=related_link\">",
"      Seafood allergies: Fish and shellfish",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_28_12747="Correlation HBV serotyp genotyp";
var content_f12_28_12747=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Correlation between HBV serotypes and genotypes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        HBV genotypes",
"       </td>",
"       <td class=\"subtitle1\">",
"        HBV serotypes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A",
"       </td>",
"       <td>",
"        adw2, adw4, ayw1, ayw2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B",
"       </td>",
"       <td>",
"        adw2, ayw1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C",
"       </td>",
"       <td>",
"        adrq+, adrq-, ayr, adw2, ayw2, ayw3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D",
"       </td>",
"       <td>",
"        adw3, ayw2, ayw3, ayw4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        E",
"       </td>",
"       <td>",
"        ayw4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        F",
"       </td>",
"       <td>",
"        adw2, adw4, ayw4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        G",
"       </td>",
"       <td>",
"        adw2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        H",
"       </td>",
"       <td>",
"        adw4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Anna SF Lok, MD and Chi-Jen Chu, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_28_12747=[""].join("\n");
var outline_f12_28_12747=null;
var title_f12_28_12748="Risks for congenital defects with maternal smoking";
var content_f12_28_12748=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Increased risk for selected congenital defects conferred by maternal smoking during pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Congenital defect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Odds ratio",
"       </td>",
"       <td class=\"subtitle1\">",
"        95% confidence interval (CI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastroschisis",
"       </td>",
"       <td class=\"centered\">",
"        1.50",
"       </td>",
"       <td class=\"centered\">",
"        1.28-1.76",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal hernia (umbilical, inguinal, or ventral)",
"       </td>",
"       <td class=\"centered\">",
"        1.40",
"       </td>",
"       <td class=\"centered\">",
"        1.23-1.59",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Craniosynostosis",
"       </td>",
"       <td class=\"centered\">",
"        1.33",
"       </td>",
"       <td class=\"centered\">",
"        1.03-1.73",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral clefts",
"       </td>",
"       <td class=\"centered\">",
"        1.28",
"       </td>",
"       <td class=\"centered\">",
"        1.20-1.36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Limb reduction",
"       </td>",
"       <td class=\"centered\">",
"        1.26",
"       </td>",
"       <td class=\"centered\">",
"        1.15-1.39",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clubfoot",
"       </td>",
"       <td class=\"centered\">",
"        1.25",
"       </td>",
"       <td class=\"centered\">",
"        1.10-1.47",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eye",
"       </td>",
"       <td class=\"centered\">",
"        1.25",
"       </td>",
"       <td class=\"centered\">",
"        1.11-1.40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Digit anomaly",
"       </td>",
"       <td class=\"centered\">",
"        1.18",
"       </td>",
"       <td class=\"centered\">",
"        0.99-1.41",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryptorchidism",
"       </td>",
"       <td class=\"centered\">",
"        1.13",
"       </td>",
"       <td class=\"centered\">",
"        1.02-1.25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiovascular",
"       </td>",
"       <td class=\"centered\">",
"        1.09",
"       </td>",
"       <td class=\"centered\">",
"        1.02-1.17",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Hackshaw A, Rodeck C, Boniface S. Maternal smoking in pregnancy and birth defects:&nbsp;A systematic review based on 173,687 malformed cases and 11.7 million controls. Hum Reprod Update 2011; 17:589.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_28_12748=[""].join("\n");
var outline_f12_28_12748=null;
var title_f12_28_12749="Surv SEER by receptor status";
var content_f12_28_12749=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F69786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F69786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Five-year and ten-year breast cancer-specific survival by hormone receptor status and disease stage in a series of 205,736 women with breast cancer in the SEER database",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Disease stage at diagnosis",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        n",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Cancer specific survival, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        ER+ PR+",
"       </td>",
"       <td class=\"subtitle2\">",
"        ER+ PR-",
"       </td>",
"       <td class=\"subtitle2\">",
"        ER- PR+",
"       </td>",
"       <td class=\"subtitle2\">",
"        ER- PR-",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Stage I",
"       </td>",
"       <td rowspan=\"3\">",
"        68,283",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Five year",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        93",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ten year",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Stage II",
"       </td>",
"       <td rowspan=\"3\">",
"        58,784",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Five year",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        76",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ten year",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Stage III",
"       </td>",
"       <td rowspan=\"3\">",
"        10,548",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Five year",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ten year",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        37",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Stage IV",
"       </td>",
"       <td rowspan=\"3\">",
"        5,518",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Five year",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ten year",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Unstaged",
"       </td>",
"       <td rowspan=\"3\">",
"        12,787",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Five year",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ten year",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        69",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SEER: Surveillance, Epidemiology, and End Results Database of the National Cancer Institute; ER: estrogen receptor; PR: progesterone receptor.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Grann VR, et al. Cancer 2005; 103:2241.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_28_12749=[""].join("\n");
var outline_f12_28_12749=null;
var title_f12_28_12750="Perinatal mortality US";
var content_f12_28_12750=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Perinatal mortality rates: United States, 1990 to 2005",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 370px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    NOTE: Perinatal I includes infant deaths less than 7 days of age and fetal deaths 28 weeks or more. Perinatal II includes infants less than 28 days of age and fetal deaths 20 weeks or more.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: MacDorman MF, Kirmeyer S. Fetal and perinatal mortality, United States, 2005. Natl Vital Stat Rep 2009; 57:1. Accessed on: file://www.cdc.gov/nchs/data/nvsr/nvsr57/nvsr57_08.pdf.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_28_12750=[""].join("\n");
var outline_f12_28_12750=null;
var title_f12_28_12751="DISH radiograph right hip";
var content_f12_28_12751=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F56990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F56990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right hip involvement in diffuse idiopathic skeletal hyperostosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 304px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEwAU8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5wHU+9WYOvWq61atxjtQBqaexWRSMjmustpclQCCOmK5SxA3Lkd810Vn8vH55oA6CwJLAYIx0x3+tdFp7/OpI3HuOlcxattYfNntzW3ZTqzAYwWGPQUAdbassiApxz8wb0xWrZwgH8eprE01iVLHG5eT3zWzZT7XCN09uuKAL8kBCv8pHSq20d8jGK2IkDw/3sHHrUM1uMEDrnkUAZwwew4OadGmRkk56euamliI69f8APSmH5GUEZGOg6UASbN4IOeOM96YrOx2ONq47VJb72OD9cAVEd5diDgdhQBKABGB19+1KpAbHOenTmplUPGGU5B/yaaAoPGM0ANUc5xgmrcTdDjA7Gqy4ZiTzjtmr0SBeuG5wMfSgB0WZHbOST79ParWzqCRjoT/QUWsYjThfnbtVqNOWOV5GOOM/T9KAEt1Hmbh9ztjtViKPDgtkkDIxxmkgQ7VGCuASB6fWr0cRJBzuzjk/0oAnhXC4OfXFWo24xkjA4AquVwRzgnrxVhFwSR8rdM0AXLfpgc9c4FW0fbMVJ+6B+IqtajKgnooJ6dKkiyzs7dOlAF4jI5qMIASDtA9BQJQRkDgCqIYyFyxyDzj2oAnvJT5ZSJgB0JFYkxKv8rEnvkY//VWsyuATEuAeSe9Z96u/DDHGD/8AqoAogsCc/Njqf6VetpAuCCWz61QEbFiH456VoW0DlMKuM9TQAqOwO5SQR0IrVhZbu2w3B6HHUGqgtQi/vCBn9KVLm3t1yHAY+9AEc9lInQcDuKtQwlMBu3TNLDqNvKdvmKDj1qxCEILRsCD3BoAepG3A5IHSh13dc/hS4NB+8OKAEK/uyo9MCkjXbhR2FPpByM+tAC01mwRTuc+1BGetAH5kLVqAcfyqqtW4OozQBpWpClTiuhtCcKe7c/hXOwdB2NdBYOHjUcgp+dAGzAfnHBxW3ZkEp39R0rEgAbBGcDtWxabjt2jJJ7UAdTpsreYFOQBx9RW5HkMMH9OormrNjhMtz156VvxSebCGOeCAeaANvSrgqwQ52DnBrYmw4Bx8vsOnFcxbFdy4OATjOa37GUjCMx3Z5J70ALNBlSwUbQeo7VVeAMSMDPdjwK1yisFPZeOP51We2Ib5N2Qcf/roAzpi9suY1+Y1lSTSKxJY5zzWzqCHJxkMB0zXPXIAc7jnHcDrQBpaXc/vMOQUfjDetaE8RUg5+U/h+FczBO0cqgLwTya6mznS5gyMbhgHPNADIQS2cjjmrkOcnAwRxjrTHRlk39O4HarNtFhgVHfC7j+tAFyFCMh84bpU6AtgkfQmkgCswzk46N2PuKtxqSQu3IHU+lAD4FJI44LZBHFXYh3A4B7VFHGFUfofarEYJwOg7ADFACBfnOeoOeBUwwcL1P16mnJGM8nJwcmrcMY3Lj9aAJbeMrDk9cVLICI1KjjHr1py45UE5IxTC/7kHnAFAFRmZQ27OfQj0pjth1aP0yR3Bp8o3Z9OnHb1qOPcnzOSdpP4UASykbAFzv4A5ztpl0C0SjIJHDH196AGXeQcfLnPpUb4KEEYyetACQRjjbjaOKuyypbRhkXe56e1UxJhSSQT6gdB24qNVJ3MzfL1z3oAiujcXOS0jY64zgCqElsRkvkZyT7irtxcAZSEbj71i6hLI6giTDfX/OKAFkNvbEMWCfjyfwrW0nUoGT9zMC/Rs8YFcHcbXk5O5s9TV3TbhUViNwPTigD0ZNQ24B2v16NU638JxvymfWuQtJ5QgMgKnHc5zU32v51LDCZ6560Adl5iA4Lrnr1pwIPQ1ys939oIZDzjAHSrsOpPHCoYBj044oA3ajncpHleuayJdbAXcqkDHfmsi/8AEM758lNvPHc4pN2VwPz5QjjvVqE8iqUZ5FWoGpgalscsoFbmnvskPoeDWDadc1sWR6elAHUWRwnbBFa9oNp3Z5PtWLp7+YhyuStbdqeMHHT8qANe2JwBg4I79q2tPPQAcEce/tWHajldoyOlbFqSJB0PPrQBrRkA4HAP+cVpWku0rzyPfpWVERk56A4GavW2DgMox1z1oA6azbCng7vXP8qV05yODjLDOKpWM5BIbknA9hV85J6EZ/z+VAFeW386MnPTjpz9K53ULQ4yDnP5V16IwP3QSe+cVm6rbscFvuk8mgDjWt5FPIJGcf8A163dCHlyAMduRz6VE9qA43K3J6VLCxgcBMkf1oA6ARAMONwxnp6+lOiQ/KhAxjB7VNYgvaIcA+xHI5qRgUUMBg/19aAJYVxwwJ55z3NaEIGTxkcHPrVCEHO7YOepJrSt0IbgY74/rQBPGvzY9OR61ZhBA5qIJjtyR1Percas3DAZx2oAWMAnjg9R/wDXqYkKQBjpkZ7UixAABR+lOkB+bA3f19KAFWTYu4Z2555pVZZDtXB74xSrCSpUAgtzmpo4MY54Bz05oAoXKkE8Hpx60IQoxJhT1Iq1eXdrCrea6lh/CDzXP3uu7gfI2onbb3+poA2GYAMAVUHpUUULsvyJkjue3/1q53+27pmypP1IFPTVLpxsncsh6j0oA33jjRB5kgY9SqHJqheTfKDjgZ47VHCVcFs+naoLl8uQD82MDmgDOvrp2RuSo64HX86wby4YgF3b6da1r4lGztyeoxzWHePjLGPb6E0AU5SSc7Rz+FTabMDOmWBjyAR3I9PrWNe3LLyHbrnANLpd9+/2t82T+VAHfSXZubpihGCcBQMAAcVP5ewFiDwcdaxbGPPzAjaOcr61oTTmMhcgg9c0AXonwAQTgZx3oWfYRwduT17Vnwz443fN1Jq1JvcAZB70AWr0oqJJECEYAsucflWbcRxqhIm9OCu6k1C9ZLUqzDrgAnt7VhyXZf5GQMnTb94GpkrppAfFKnmrUB55qoDzViI4PH1qgNe0YcVsWZ6cc1h2prZtH7UAb1jL5RHUD+ddBbPuUbBk45zXLQPx29AK1LG5aNwByM4oA6q1lyFILcdcVt2zK/HB4zmuegYEAhwQeg61sWLOX6NzwNvp70AbELMVx1x2q5C2w9cA1lxT7ZCoPA4zVpHJU4J49KAOgtJjlRuG71xWvbXAAAfO4fd5rk7aVlxjGOvWt6zcPDnOPXntQBsoMyfKc47dOasyRiSArIAy4zu64NVIceXuVsZGOfarcT5Qhj16j0oAzZrBgPk+ZDwATzUQ087hGFwemSOv+ea3CgBUkgY/WnIoX72TkHgdqAIYo0t7dQAQR0Y96fCg5dhknpnuaeoLMMDLY4XNShRgBSQFPHuaAI41bOcHHueBV21OflwSB6noaYkZPGMD69anTcvGTz2AoAuxDce2R1z0qyq/NnqcVVi9P/1e1XEXco4OD2HrQBOo3ce3rSyDDZORg05FCEtjnpVXVb2KztjM5BbHyrn1oALzUrfT4t90+1j0XqT9PaudvPEjzf6lwkecYX+prndUuZ7ucyytuZuB7D/Cqajb6c0Aa11e+fnywOnUVSaQDAVsv2J71CxYH7wKAdB601DukBbknt1oA0bV0C8lvxOamZgBg9OvXis9Wxxjp+lHmCQj5s49f5UAb6t+4QAnLcn3qpeTCCM/MGJFCyYVVB5Awcd6x9Xnyr46Y7UAU5LwGdiM+mAf61n3dyJGwpb5eAR0+lVHl2sxBxk8cfrUUbZPJ796AK+oW1ySXX516/5xTdFVpJwdpAHfpkVrodyYbHPBzQQsK5jK7c5I9KAOi0pPLViwBJHB7D/P9KLmddxzjjgVBDeGGCEcZC55/rVWeZHlHPPfA6igC2k4D/McDqK1zMjqGXuM/jXM3Mnyjpjb1FW7WY/ZBklsdcevWgCLXnaLafnJwD05waxkuXjAMaHd6Vqajc+ZPJk5XPAz0+lZb/KxA659KTV0B8gCpoqgFSxnmmBp2r9OcVs2zcZ79KwYDyOta9s2VGevegDbtiSAe38q0YG5zzkdqyLd8Aev6VsaXYXuo7zY2dzdbMbvJiZ9uemcDjODQBv6dOqr8w/+vWzaX8NvCHLMC4OF71hQaPrMSMW0nUETHObZ8dOe1VfOLN1IH9KAO0trpJyGjwc9xxWhDIMgAEqe1cnYzeXGEB689etblneqCELEgdOPzoA6C26/jwa2LSQthOje461ykepweYquwUn1OBW9p1wqSIvmZLLxxw1AHT2LkgCRSD93mry5GCOTnjniqVncRzAHo+MEYrWVQ6A7dvTkUAOibgBwMHnnmpGZVQkEAA555x+NV2JAGOAfzojGCf4snoe4oAljJLZHJPRjU6IxJGMkdScVGiGPPP4dsVcRlkQbyAwGPTigB9uVY5xnHTPFWI1LvkYJz69KrDcPu8LjnAqyqnAZcDPIoAmgQ+ZwDj3rQhCgD9PaqSt03Ht17/jVm3kJJ4+bGff8aALSr8ozwPSvOPE2oSXl9LtOYVJVMdD6mu81q5+y6VcS5wwTA+p4/rXmE04IYZ464xQBXUtvfe2AP88Ut3Ljbsz0xgVWefLbic57U4OpPIz6UAKbl0wobjpzzUsU+VyCDn9apSopPt0pA6pkZ7UAXZJto7sPpioxOQxxn5uKz3n/AIQRwegqSJvlDMfm64xQB0VvKz2+SecYODWVqDbw2MBR0H9Kjt7oIkgJPTI5qvLOXXs2efrQBRkXOTjcOtNjU89MfSlJYsF9RxVqKLClievTjrQBCZUjADsBkcU6IqZFYkFT1XtVa4gd5juyc8c1NEqh9o44yKALM1wOqngnkelV1mUyEnJ56U24QeWe2R1rNikIYoxwQT170AbHm7l56j8a0LWQm3K5BzzxWLG+SQelaNq37vIx0+lABcBActjPp61k3D7snliTnrWjfDCMx4IHpxXOPcbJMjr6UAfLYqVFPXtTBxU0LY+lAFiA4NadsSWAHJJwMVnhBwVPBrf0nXrvTbQQ2CwWsvO65jjHnnPYOeV/4Dj3oA3rbQbiGNZdWli0yEjKm5JEjj1WMZY/UgDnrXc/DTxJoehalcWwkuVt7lcvd3BAG5c7QEGdowW7k5IryRZnlkLyuzyMcszHJJ9eatxv0we1AHpvjTx5Nrcj2mnloNNzg9mm9z6D2/P25aNyAOn+FZML/LjrV1HBGc8UAbdtOuwqWw3bmr1ncAYyfmbP4CsCKQnp6cVagY7sE+9AG08iuSV7cDjtWvo9+ynynbP9056Vz1uSeR09KuRbw4xgUAekaVe/IuCSoPJB5rrtNu/3YyBtJ7HIFeX+GjdXBkiWNnJGVcDjj1NeqaHpc8elJLcBRKCcL2x70AWpiWBxjOM5x/Ko4gwJC8Y5IqcpsAOeOOnAqRF3EMQQ2flX+VADAwGwAnPXApdxP3hg9ck9Kc6kOxPBz1xUEnO7Ab0yOcigCZGMTHaWAxkg+n9auxTO/cb/AL1ZVuDk7WBbJxt9+9aEbEoQwQMeSRxQBpK4K4Yrk9s9OKswqVkAbPPFYW8nDRjDZGOa1bK7AKhm46ZPWgCv44YpoDenmIDmvLppDg7jjPfrXq/i2MT+HrgryFAcfga8iuHADAq2etAFaaTlTnJ/pT4LnpuPQVTd8Hp0HrioEl+YnPFAGhJcfP7nr7/jTfNJUgt161nSXBJbkYPp6U37SRgA47Z9KANKFkLMSdxxzmppHIjyufzrNimAQlj0PSpmuU8ojrmgBzTMoDDGc05ZcnjAz1FVWJdMnGD+lEZ2soIyDQBfiC7uvNX4QGTDdc9RWbH1Xk/jVtJAg69aAJJo9xAByw9aiijKPmQgZ4+tWFIOC3JFNldfl3YCjqR/hQAy+2vGCBjHGK52cFSAo+Zeozmti7nCcA5464rGmkDZHDUAWrSUHgdhg+grTtWJGDx2PvmsOBfn+UE4rTssqw3HAPOKAJ9RmyrbV6Dgetc9eQNuHoe2ea6a6AeEqDznv3rIljJbDY9uaAPk80+M4NMNKvWgDQgbjBqwh5qjC3FWY35oA0Im54q0jnNZ8J55qyp5HfNAGpC+BV6Fs9TgVkxMOhPSugsbvT7qGO3v4xbSINqXUK5H/A07/Uc+xoASKTJ78VfiYhcY+lR/2PeJPDHFH56zttgeE7kk/wB0/wAwcEd8VNeWs9hdyWl3GY5Y2wy+nv7igDRtCzlQgJJ7Cux0TRY22yXnzt2jBwAPUnv9KwPCKI91ublugr0axgAcAYHQLkZx+NAF/RIvLlQp8ip+GPbArqxqQH7tD+7x+XqKwra2cxsIwcgYwMVNpa7Lw28o5UcbvegDVuXkKReWCUc4JxV6FsoDjtVqa0McCCONm46EcnNPstNl2gHK+xFAFRYllb5jggetRTQvu2jPTuK6KPT4l++dxHfvU3kQt908dOtAHLQDccse55GBVo4ZMOPl/vY6e1as2mb2BDkdeO1QTWBVNkfPGDnvQBkuMFlXGSeq8cdqjWYo4ByG7AnrT3JU5PY4wB0x1xVS4JLhhufb6enrQB1Fpi90mWBjuO0ofxHFeQavAYbiZWXG04PtXqHhq5HneWSTuBGT6jn+Vcp8QLD7PqDzAkJL8340AcDM+5TjqR1NZskm0EZ4+taU8QwTj2rMuo9ik+nbFAFTz/m59T61JE5dwc4J4wKrrHu5BwCelW4dsXp7UATSYAwMnHNLFIcY3cjjmoHcEAnAz6c00N8+7uKALpmIABz6cU5JPnz+maz3kJbk9OTikll7Lyc9RQBri42gkE7s1PBLkAk81grIwQE5x6f41dt5vlweDnqKAN6O4GAN2DiopZweOM1m+aWXANI0jA9cfUUAWbkiRPTj0zWd5MhkJO4jP41NLexRp8zfP/dHWobS4nmlz5eI/T/69AF60h46EkDGRV9Uxz6jOPSmIg3Bj1qyMZAIA/rQA09Dn6VRnOXIz+XWrFzIFOAQPp0/z71nSswOQc+tAHyhTqZmlHNAEsbVaibmqKnBqwjcCgDQibjirMb/ADe/WqETnHNWEfnPWgDRjfA44FWYpAxA4wKzBIMc/wD6qs278ZJoA9F+HHiGy0G9un1Brjy5ECoI+VBzySM9fz6mus8U3eg+JrIT2V/BHfwj5fNzHvH9wlsD6f8A168cgYkZJArQjmAC4xx2oA6/w1c+TeJuAKk8nPSvUtP1KGVlIHI59c14hpt8sMgcjcO4rq9N1x5LmIRqyqSAADyaAPc9HmR7ceUjLuPcfd+tbVtaWsTb5NrFuu/vXnenaky3CiJjnOAAa3pNaUSMJH+ZMDI7+tAHpK3KCIKnVQBzVQXU8jlV55NcxpOrGUhnQ+XnILHn8B/jXT2t9AyDaNpPegCW2E5HzrtJ9eKWWKVj94D6GpoplY/Lzn0pxcH8/SgDPeS4jBY5IBwSp5po1CTdhsZHBDCp5OvHU8ciq0qqQfMUN+lACXQt54i23DL82M96xVZXkaIAg9s9DVu9Vo0PlEtx909qxJfNUlgc88gHkUAaNm5tbr7u0qRj8DWr4rsRqemsEGXVd6HHUVjWk/nELOu454k7j/EV01tzYRMeWjypxQB4hdQvH5iuPmU461n3SK0OD09q7fx3p32W/eSMYjkGQwriJG3HHQf0oAyx+6Ht2qvK5ZhzgZqzeYD/ADZKjtWfK6Eck4HT6UATNJkcKAPUUxZxnAznt7VE7lkAwRnr7VEg2gE5x1570AStK7Nhi2D6UplKt8xqCVC33W9gfakIO0HHNAFlr7y1JYYAHNZZ1tJHIyR6c0+4iLo4/MDvXI3cE8E+QM80AdvBrYRss+7PQGt+3nS8tg8TcsK8oLSNjIYH8q6HRbq5tkbYx2e44oA7i308LKCyrlurHmtRImiA2RDa3cGuftb2U4IYFMYBq7HfS4+bI7/KaANmCWQDmItzipi/yklVDnjaWxx/jWOLgzBclvTrnFTLJ0II6fWgBLnfvcyLnnvVUTANgNx2z271Yn+Yjufeqdzjy92ASDzj1oA+WR9RT0YL2yaipwoAeOtXobG7fTpL+OFms4pBHJIvIRiON3pnsTwaoCtDRdVutHu/tFk4BI2SRuu5JUPVHU8Mp9DQAyNsVMJOeCM1ujQ4vETCfwnCxumI87S926SLJ+9GT9+PJ78r3yPmqLxl4S1PwffwWmrCMtNEJUeIkqfUZx1B4P4etAGYkhIxVyFuKzIW+YZ7Veg7HHFAGnC+Mc/TmrImAHFZ4kwPXNPV9vU80AadtL8+DXT+HpAL6Dcw27siuNhkOMmtiynKsrZ5B60Aeu2N7HYnzHb96R8vzfd+tXrC6E8wlck7juxnqfWvPdLvJLqQR8BerMTxiussGO4EnJxkHoPoKAPR9NkO0GIlt3G31rpLLJXD9e3NcRo18FEQBXJ59a6q1vVIWRTk4xz2oA6e2cICCfxqwk24nnjHrWBFeCRwTwf51pW8oLcHHuPX0oAtseevP1qvcrhR6gZGKmchgGyCM/pUMhIXGeg59KAM+SQnG459qr3CIY2kZdpyNrevtTpuZGYjnPYe9Mvj5NhngMeR/wDqoAyftBjlZQwxgjOOK6rRLnzbWVGO7gMD1yOlcJK7Cbkk7yGx3rpfCEwW4WNeI3BU+x+lAD/EtqNQ0yWMlTLEMrx1rx26IimcPng45r2PUZDDdvk4PNebePNN8iQXtuv7iT5iAPumgDjNRuOhGR2OKyWlO7gVYuZN6nOcj1rOJ3OM80AXIZTgDJOB0NMlDF+4GaaZAMEfrS8dc8e9AE8RwuGPGR3pd2G3biT04PNVt/UE4zzmhnJBCnHrQBNLMAMFRiqE6xv94A/WhycYwQKgYEjPPTp0oAUQwI3IyO4JqYKHUfZjhfQ1VZCDwMj3p8JZGBX86ANiCZiuMEMAOMVrLnjPQeprDt5yox0z39K07adRGCyozYyAWx+lAF4M+4Y6dKmDMx4OPxqtbymRgPs6jnJBf+Rq4xTaxyikD60AIztgdW9Tmq8rsevAHPFLI49Rj+YqF5F5wR1x8tAHzFQKKSgCQH1pRTVPFOFAHWfDfxang3xAdSbTo75jEYgGk2FMkZKnB5wMdO5r1Txl4w8JfEfws9p9pOnaxB++tRersG8dV3jKgN05I7HtXgKAswA71tWWmhkDSDjvmgCnEpBOe3FXYAzD5AWPsK0f7NiWPzCSQOQvSlRMKdx2J2A4oAqZK53ZB+nSmmTJA7DpVx7iMjaVyuODms8keZwcjtQBfgPGT1rStnGOfyrJgIxz1NaVsDlfQ0AddokiJbFWGZH5U9PwrqLKfYoA5IwSM81ytjEVjjJHVc5HGBWxa78FckL6nvQB2Om3+4qX/HaehrqbDUlwqlRjrwOprzuCUBcltoHUZ61s2Fw2VKng9jzQB6PZThnCqMMTwBXQ2smAcnnOf1rz/TL6QlGHJHPXpXU6deq6BpOD0zmgDptwKH1PAPrVaWVlYBh1461Ck3uRyfemyyBgCCD3NADWG48EDHIxTruEz2oEZUsBnHQ1GSGIK856U+AMOCSuM9+lAHK3EIinXzNwAG08YINa+hqYbyNkGUI+VsjoK0b2xFzA4lPI+6c1nafHJFOFJwnYDoaANDxYgWeKTgCQGuOe4SWJ7Of5o242t/Su28UJv0KGXjdG+DXmV25R2bJABz6H/wDXQBwfiKxk03UHgbJRjlG9VrGIAlORgn9K9F1ER61p7QttS4TmN/7p9/615rdJJbXEkVwpSVGw6nrQAsjHs3H6VJC/X6c1UMmeT1NPRhuzmgCznnHIBpf59qQ8ng0rDHJzQApXPQ5FM2DPJ59KUsc46L9KZuPTODnnNAAI9/qPSn7VD4BH4UsRAXIzn61G74bOB9fUUAPQEOOQT/KrDFlBO4kjuO1QKVU84JPv0qeHb0xycDJ7igCNZp4zuBHPp3rQs57mU5ZiB36D8qr+QC4AbJB4GO9aESFU4AB9jQA9mIG5/wAu1QPIFHAAyfzpJn2r0H0FUZ58D7340AfPtLSUUAOFOFMFOFAF3TlBlLHkKOma6m0kZ0jCJz2Arl7IYX8etatveiB/lOMUAb4ieKB5GVnDccjFZl/K5Vt2AB6VZh8S3EXdHXGCGGc1FcTW15DIVQRS43bQeDQBj+bk01HBb2zxTxHFk/KQfrUluiKR+6BNAE1sTnAyea6jR9LadlkuB5cPGQTyay9OKIfuoPU10tpcnaHbOQPl7UAbkjIGAXA4GAOvT9KckqhcAknissTb2K7m5/hz196kicKRkgAdwKAN23mUkZwc9y2T7VqWjqCCCQecYP8AOubtnznBJHvWxZyL5KjnI9e9AHV2EzRsCGHPAGc10dndgIv+yc4Hfqa4ezmOSwBIH3cevb+dalreqrNlmYJnn3oA7i21DkbiDj1NWkug+fmIPZgelcbDekBQTg4AI9Kv21yryna4xnoD1oA6+0fewQ/eH61pAAcYzn3rK0iN5I95HB+6Txn3q/IVj4YknvntQBIz/u34BGMYA6e1Ms4VeQeUcj7x5x9KrvdoUI6Hpk9qsaWVUsysGOCPpQBNqKfaPDN9GoO5Dv49jk/1rx3XLjE3lx5IJy2DzXtmngS2l4jAlWQ5FeEa7B5N/Kj5BRiM+vPegBlvMFZTzn6dapeK9LGpR/abZcXcafMo/wCWij+ooRnG3HK+g9KtQyjKkyPGQcg9fwoA813FSVwSc4qaJtv3zjFdZ4o0T7RHJfWEe2VRmaMDk+4rh/MIOM856HrQBrxzBk44xwaXOF4P51mJMY2+U81bim3YFAE7HjNMZuTyPrTWYc46EVGW7E9KALQf5CSeMd6haQ789uhz2pu7pnOetRyMM98nr6UAWI8HG4hsH0rVRAADjg9zWHFNg8DPOMVr28plTnj3HegC9BycH+E/mKnL4XcOPeqiE8c+2ac0y5IwM+poAhu5FHXGM9Ky5ZMntgVavnIUjgVktKRnH5UAeMUUUUAFOHWm05etAF61IAOegHPvSNLnJNQKcLxSbufegC0khOc1dtJP3ikHp2rKV+farlpIQ4PYc0AbhtFaPcgYVTAKNjJ5qa2vMnaVG3uM064VY5NyjhhkYoAs2qlSGbOf4R/WtWGZyAMkntWJDJkjJ5PU5q8kvHy8E0Aa8VzgkZyTyeatxz/Nwfx6msJTkDnp1Aq9aZyCfxoA6K2kXaCcflWraOSEGcAnHB6D1rn4nLHHH41s2+dy9CAPy7f4UAbkVwVUEDPORxVu2nBCorA4znvisxyUjZizdMf0FVTK0LBwQe2cdKANx74gZAOT0/xrY0BzM/mSyfIv61xbzM7ZbO01s6HdSIgLEEZ24xQB7XZTo1kj4JOM9sGq1zeOwBjzu3cLjrUHhW8ivrNYM5dRjHqK6C20ZIyZH3MzjAHp/wDWoA5q6lxGEjYMwPI96s+H7oveEKrqMfNkU3WLKCxSRp5hvPOB1PtxXInURBITbFtrHk57elAHsNkipvRRguDkY6GvCPEsLNrt6FkBAkI+Y16F4X19vtEccsnDN3bPFeR+ItSdPE+qxO7o6XDgKeQ3P6UARkeUxBGMHOSeKXIPJx061V/tDd94846inx3CkjP1A/woAv2dy4kQcEkd+/sfyrC1zQYtRVrrTFCXWMvb/wB73FaTSRkK8ZIAOT7H2qpPO8NwGTOc7lPpn0oA4F2khkZJQVkU4II5H1qVZ+mDz3xXb36afrUSjUo/LnHCzxDDD6juK5W/8M3lszSWcsd1EDn5ThvxX/CgCBbgjqcj3p/nqcEnGT0NZcjSRNtmVkPowxTfOB56+lAG2ZFK/UdfSokcMQCc4PXNUvNJTAIB/lTQ7cEcH19aALxIZ8Yx+PatG2mUFVVsKBxntWKrYU/pUnnbhjbjHp3FAG4s4PK9ARipPPO4kqR9TWPDMfLHoBwKkSfpk4JHSgCxczbhxwOn1rInkOMjHtip7qY7ztbPrWXcyEr0J56dKAPM6KSloAKctNp44FADiaO9NzS0AOFTRNge5qAVKnWgC9AxBwM1fST5CoPB5IrLjYZwxOPWrcchzgk0AWQ2PujGO3WrEEhUcntVIseueM4NToSen50AacEwCgEc+lXoJSGAB4z2rEiJByeh71oWpO8E8/QUAdPZHcQzYxz0rfsIQY9zEqSMhf1rn9OIKgjk9MHvXW2iCODMgxx1/nQAMyBcyk7V6/0Fc/qWqxKSA3TjHWqninWvJHkxMAT0x/OuWWUtliTQB0cWssmQVDKfU5xW7pGuRLks5916GuA8zJyTgVLb3LK4Knge9AHteieOILExNBG7SDjriuvi8Z3Wo2xlEroCMjAORjqDXg9g6/Lg5Xg13eiX5REXdgYI/wAKAO5vLwz2sZdwzDqT1z71zF1K0crlQ2Dg8d6t290ph5PI7enNV5ptrsOQvcE9RQBLp17LbXCYODuBXHsa5j4mJ5XiZ7tOI72JZ1/3ujD8xW3LmNPORiR7dvSsfxep1Lw+WXm4sG8xcddh+8Pw4NAHLR3zIMZLCrkN4pxlvwzz+Fc6svsQRTzKQvOeP0oA6mG7YMG/1igEZ7471cJSaPdGfkBJx6f/AFq5CK+aIjuO/rWpDe/cmhIB5zQA+4BiI+bORg4+tRC6ICgMQ3tWmkcWqRHyCsdyOqZ4Y+orDuLeWGRhIpVgc45zQBNJqLsmydElH+0AR+FUn+xTEl7aNT7ZWo3HfHPrVWTIYg5yeDmgC6bSzZMqHUnqN/FN+xxqAAJfbmq8cpB25z2+tWPtG4rvA46cUAC2sbBdobn3q3HprvkheACeOuKYdxQEjPtnFXbV/LtrqRic7Qoz6nr+goApLDknYB6nmnrbbiS5II5IxVnQsGOcsWxtAwODUztu5C554HSgDMmtEb7xYH6/pVF7ODPzByPr0rWu32Z3Dn6Vm3Mrbj2B74oA8ipKKKAFp/8ACKjp/bHNACilpAaXvQA4U9SQfamDrTh1oAmQ9zVlHGcnk1TUgDHepozkj680AXUOVGDx0xU6EALn6VViYYAI4NTryBn6UAWF3E47VoWe4nb71TjHO0jr+tacKH+EHPTNAHT6DHlxI+doGavavqohi25wBUVlG8FkMDlup/D1rjfFd4yKEB6nH0FAGfqN79pu3ctnnANEE3UZrDaQ7uDUsV0E+8KAN4t8uO9OibqB+orOhm385q3G4JGTjAoA6HTJiylD1XkfSuq0ic/MFOWWuAtbgxyq654611uh3Mf2lCx+VunsfegDsYrkrbMzHLdB+VC3TtGA74BwRntWVdS7SATjb3HQ1SkvM4AYknn2oA6A3xQjDDAxwe9KJw0xdPusNrofQjFc4LkBlweOTzVuK42qhVvmx160AYWsad9ivXiU7oydyH/ZP+FZjll45OOa7PUoEvLJdvDDlW7iuOuQY3McgKuOSKAIN2WPPNWLaUgFCSAfbiqcjLjI/OoVmCsufpmgDTN3JFIGiYgg/Q10tpqiXliDcJvbO1h/ED7GuNaZAuQ2an0+9McUo5Af174oA25xC8hEOSp7dxWZc/KcAetNS5YPngHOcirE0sU6DdnfnJAoApROARkA56GpI3xlulQbcFgMg56VaihdwCvQcmgC3bS5+XHFasqLHo8xI43AA/gay40VIQu7Jz07Gr+pSBdDdO4dTQAeHxiK62jdleO4FTSMVQblAwehHWm+Htg064l+bcfl69OeatKiyxYjwSM/LQBhTThycZyT3qlOeRnJyOlXryE7mKjA7g9jWbMcEKo3EjqaAPK+1JRRQAUvvRR2oAX6U5Tn600HmlA9KAJBThTAfWnUAO/Onoefeo/pSg8UAW1bA/Cr1v8AMoIGSOorPR/lGau22QR2ycUAX7Yknp+GK6DSYt80ZOcZHQ96xLVcHp3rrdBjPnq393NAHQXqrDajA4C9PWvKvFM/m3gGSdpIr1DV3AsSxxgKTkdq8Z1Ofz72Vh03HFAFc9e1IxHU9aOgzTCcmgCZZGXgVat7xgfm5HtVHGB7+tOQ88UAdBBco+Pmx7VvaTc7JkOeh6+lcXG2O9XbW7kiOUfjoQaAPTLm5MkCtuO0j16Vn+fhyMH+WTWVYa3GyIkgUKOwP61ce6iJDxurKwxzjOaALHngN6n3q5HOAMlqxy6vGxDdCOh70SSAHGcY5oA6W3vlUlc/Keo/rVTUpFBKSIkoHIJXqPrWTHNjJVj1yKeLkXCGN3+cDKNnGfagCvcCDJITA/2c1Rkt42BKylfYjrUk8hViWyD6e9Vmbd8w6/XpQAht2AOXXB5qTb5cYwScDFRLKD+HrQ0uDznFAE0bsCMntUokKnIPJ/SqfnAg9ie9N83nAYDHTnrQBpCY+Zljg+oq1FOduM9B1z+tZaEunPTp7irkHI8snABxn1oAv2gcvwctnjJq9rjldOCjGCys2PWqUTojYAYjqar65dExLHkdRwO3FAG5oDEaPOqnkvjPtRE7o7uCynNZOh3DG2MUblWV92QePxrTMjNkheT3oAj1OdphkkAdhisWZvKG4kM/atG9JI5HtmsO5lAyRwPQUAecUUUUAFLSUtABT15+tR05Dg0APFKDigikoAd14pwxUfSnA0ATo3SrsDncPXNZ8ZAPIFXbYZIIzigDobBQ2zH4mux0cBIy5UZPrXI6R95eSDnk12MHyqOuAB+NADfF05Hh652Y37Cq++a8fzz716L4sv2jgjtkJ3FtzenfiuJnjErE7QrdeBjP1oAoOeOuaaDzyKc4xjHQ0welADywpyDBB9e9MP60qEZ96ALAIIFSJJjoagByMg0uO9AEwckk96t2d4QQkvKHjrVID04pB0FAHV2U0sTExkSxv29KnuLxmPmCMgFuVH8PHSuUguZYG3RSFcHNb1lqkV1tSVQk3ZgOKALSXSFCA3PvQZgp6nOfWobi3dUMiKGjJ6r71nAnJ2kqcZz60Ab0uLlNx4cDqO9UJchjjNVobqWI4649aWW5BcllIHXAoAVmOM9D15qNpTgDHGPSq73afw/KOuSKha5UqQH60AWzMOc0ikhhj/8AXVEyc9ePrU8UiDnHFAGraksw657j0rWVI0wZWCj1JxXMNqhQYi+U+tVp7x5f9Y5PseaAOnudajj/AHcSgqOOOfxrNu77zcHlgPWsQT8k08TUAbVvfNCD1GcdO1bWnayGZQ5Ye4FcmZMoBg0JMQPagDvZbmOeFgroSOhzXM37FJNuCue1Zpu3A+8fSmLfMTtlwy+9AHMUUUUAFFFFAC0CkpaALCDfGcdRzTCMcU60bEgHapJ49n40AQUClP0pKAHocEZNaFr94etZtWbaUxkDGRQB12kLmRQDxiurgfhRgcc/hXK6A2/aQ2QR0rpWOyBmwMAE9aAOJ167MuoTtu3YJA9KzIpAWGSMDtSzuJZpWPdiePrVKYlRgY54oAjkfJ4PFNBptKDQA6nr61GKcGoAlGPWlB71EGxj0oDc570AWM03JxUYf8BTlOOvWgB45zmnqxUgqSCKhDgk+lSKRjgcD2oA07TVLiAlVbCt95R3q5Ff20vEkASQ/wAQPBP9KwQ+0cU0vk0AdM5tnH31Bx/EcGqc8e4Ha3Q9+KwmbinCeReNzY9M0AWpVIPOKquQDURlOeeaY7lup/CgCQv6cUhlYjG41FRmgB4dh3pRI3rUdKD70ASiQiniZgahzzTgRxQBaNwdo4FCznjIBqGl4HvQBIZzzkDNRCY8nA+lB7+vaoTQBVooooAKKKKAClFJRQBJEcOK1LhN9ukgGfX61kL1FbdviSzYDrigDJPfFJUkgwcdKj70AKBzT4+oqMU9DyKAOo8PytE+V7jpXWXkytpspBwfLOOfwrkNBBaRQAea6PXwLfR5G6HZwOnNAHAlzzg45NVZnDMMfdHAphkLdab2oAdmgGkzzQtADwaBTaWgB2aM03NGaAHZxSg8UwmnZoAdmnbvwqPNKDjpQBIW55zSZH403OetNzQA8nPvTSeaDTSaAAmkzQTSUAKaM0lFAC5pabmloAcDTgaYDSg0ASg8YpzHrzUYOBSsetACE02gmkoAr0UUUAFFFFABRRRQAo61saS4HHrx0rGrR01gJBlgv1IoAbeJskI9DVU8VqawiBw0bowbB4YGss0AFPQc84pgI9acvJ6igDqPDXzXcYA6+lbfjGVTp5RTyxGcVkeEnjWfc0ka/LxlwKv+J2WSADfH653CgDz89elA4pW4Y02gBaVTTaUGgB9FNz3JxS5xQAtA6c0melIMUAOpRSZooAXPWlzzTaMigB1LTKWgBSaSkozQAUU3PFLQAtJRRQAtFN/A04UALSim0tADqUmmg0UAKTR2ptLQB//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiograph of the right hip in diffuse idiopathic skeletal hyperostosis showing osteophytes that arise from the greater trochanter, the superior margin of the acetabulum, and the ilium (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Esdaile, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_28_12751=[""].join("\n");
var outline_f12_28_12751=null;
